Hiroaki Mitsuya

Q: What Schools Are Affiliated With Hiroaki Mitsuya

Hiroaki Mitsuya is affiliated with the following schools: Boston University, KU Leuven, Kumamoto University, University of Hamburg, University of Warmia and Mazury in Olsztyn, University of Utah

Hiroaki Mitsuya's AcademicInfluence.com Rankings

Hiroaki Mitsuya

Biology

#1099

World Rank

#1884

Historical Rank

Virology

#98

World Rank

#101

Historical Rank

biology Degrees

Download Badge

Biology

Why Is Hiroaki Mitsuya Influential?

(Suggest an Edit or Addition)

According to Wikipedia, Hiroaki Mitsuya is a Japanese virologist famous for his role in discovery of the anti-HIV drug zidovudine as well as other anti-AIDS drugs including didanosine and zalcitabine . Mitsuya was born in Sasebo, Nagasaki and received his M.D. and Ph.D. from Kumamoto University. He joined the American National Cancer Institute in Bethesda, Maryland, in 1982, working initially on Human T-lymphotropic virus 1 before switching his attention to HIV. His identification of AZT as an anti-HIV drug, as well as the anti-HIV properties of didanosine and zalcitabine, was made in 1985. He was appointed Professor of Hematology, Rheumatology and Clinical Immunology at Kumamoto University Graduate School of Medical And Pharmaceutical Sciences.

(See a Problem?)

Hiroaki Mitsuya's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

3'-Azido-3'-deoxythymidine (BW A509U): an antiviral agent that inhibits the infectivity and cytopathic effect of human T-lymphotropic virus type III/lymphadenopathy-associated virus in vitro. (1985) (1657)
Phosphorylation of 3'-azido-3'-deoxythymidine and selective interaction of the 5'-triphosphate with human immunodeficiency virus reverse transcriptase. (1986) (1219)
Inhibition of the in vitro infectivity and cytopathic effect of human T-lymphotrophic virus type III/lymphadenopathy-associated virus (HTLV-III/LAV) by 2',3'-dideoxynucleosides. (1986) (891)
Syrian hamsters as a small animal model for SARS-CoV-2 infection and countermeasure development (2020) (773)
ADMINISTRATION OF 3'-AZIDO-3'-DEOXYTHYMIDINE, AN INHIBITOR OF HTLV-III/LAV REPLICATION, TO PATIENTS WITH AIDS OR AIDS-RELATED COMPLEX (1986) (733)
Molecular targets for AIDS therapy. (1990) (648)
Designing CD4 immunoadhesins for AIDS therapy (1989) (466)
PHASE I STUDIES OF 2',3'-DIDEOXYCYTIDINE IN SEVERE HUMAN IMMUNODEFICIENCY VIRUS INFECTION AS A SINGLE AGENT AND ALTERNATING WITH ZIDOVUDINE (AZT) (1988) (464)
Dextran sulfate suppression of viruses in the HIV family: inhibition of virion binding to CD4+ cells. (1988) (439)
Strategies for antiviral therapy in AIDS (1987) (426)
Phosphorothioate analogs of oligodeoxynucleotides: inhibitors of replication and cytopathic effects of human immunodeficiency virus. (1987) (415)
In vivo activity against HIV and favorable toxicity profile of 2',3'-dideoxyinosine. (1989) (395)
Suramin protection of T cells in vitro against infectivity and cytopathic effect of HTLV-III. (1984) (360)
Highly effective treatment of acquired immunodeficiency syndrome-related lymphoma with dose-adjusted EPOCH: impact of antiretroviral therapy suspension and tumor biology. (2003) (346)
Novel bis-Tetrahydrofuranylurethane-Containing Nonpeptidic Protease Inhibitor (PI) UIC-94017 (TMC114) with Potent Activity against Multi-PI-Resistant Human Immunodeficiency Virus In Vitro (2003) (337)
Clinical pharmacology of 3'-azido-2',3'-dideoxythymidine (zidovudine) and related dideoxynucleosides. (1989) (329)
Complete nucleotide sequences of functional clones of the AIDS virus. (1987) (321)
Replication of human immunodeficiency virus in monocytes. Granulocyte/macrophage colony-stimulating factor (GM-CSF) potentiates viral production yet enhances the antiviral effect mediated by 3'-azido- 2'3'-dideoxythymidine (AZT) and other dideoxynucleoside congeners of thymidine (1989) (283)
Kinetic characterization and cross-resistance patterns of HIV-1 protease mutants selected under drug pressure. (1995) (253)
Design of HIV protease inhibitors targeting protein backbone: an effective strategy for combating drug resistance. (2008) (230)
Spirodiketopiperazine-Based CCR5 Inhibitor Which Preserves CC-Chemokine/CCR5 Interactions and Exerts Potent Activity against R5 Human Immunodeficiency Virus Type 1 In Vitro (2004) (218)
Regulation of viral expression of human immunodeficiency virus in vitro by an antisense phosphorothioate oligodeoxynucleotide against rev (art/trs) in chronically infected cells. (1989) (215)
Infectious mutants of HTLV-III with changes in the 3' region and markedly reduced cytopathic effects. (1986) (213)
Divergent anti-human immunodeficiency virus activity and anabolic phosphorylation of 2',3'-dideoxynucleoside analogs in resting and activated human cells. (1994) (213)
Efficacy of Antibodies and Antiviral Drugs against Covid-19 Omicron Variant (2022) (211)
Long-term toxicity/activity profile of 2',3'-dideoxyinosine in AIDS or AIDS-related complex (1990) (208)
Diverse Transcriptional Response of CD4+ T Cells to Stromal Cell-Derived Factor (SDF)-1: Cell Survival Promotion and Priming Effects of SDF-1 on CD4+ T Cells1 (2001) (191)
EFFECTS OF SURAMIN ON HTLV-III/LAV INFECTION PRESENTING AS KAPOSI'S SARCOMA OR AIDS-RELATED COMPLEX: CLINICAL PHARMACOLOGY AND SUPPRESSION OF VIRUS REPLICATION IN VIVO (1985) (188)
Effect of SLCO1B3 Haplotype on Testosterone Transport and Clinical Outcome in Caucasian Patients with Androgen-Independent Prostatic Cancer (2008) (184)
Darunavir, a conceptually new HIV-1 protease inhibitor for the treatment of drug-resistant HIV. (2007) (179)
Long-term inhibition of human T-lymphotropic virus type III/lymphadenopathy-associated virus (human immunodeficiency virus) DNA synthesis and RNA expression in T cells protected by 2',3'-dideoxynucleosides in vitro. (1987) (177)
Amino Acid Substitutions in Gag Protein at Non-cleavage Sites Are Indispensable for the Development of a High Multitude of HIV-1 Resistance against Protease Inhibitors* (2002) (170)
Characterization of monocyte/macrophage subsets in the skin and peripheral blood derived from patients with systemic sclerosis (2010) (170)
Structural and Molecular Interactions of CCR5 Inhibitors with CCR5* (2006) (168)
Mechanism of hypercalcemia in adult T-cell leukemia: overexpression of receptor activator of nuclear factor kappaB ligand on adult T-cell leukemia cells. (2002) (168)
Acid-stable 2'-fluoro purine dideoxynucleosides as active agents against HIV. (1990) (159)
Age-related changes in the subsets and functions of human T lymphocytes. (1978) (157)
Correction of adenosine deaminase deficiency in cultured human T and B cells by retrovirus-mediated gene transfer. (1986) (155)
Impaired production of naive T lymphocytes in human T-cell leukemia virus type I-infected individuals: its implications in the immunodeficient state. (2001) (155)
Efficacy of Antiviral Agents against the SARS-CoV-2 Omicron Subvariant BA.2 (2022) (152)
Identification of Aberrantly Methylated Genes in Association with Adult T-Cell Leukemia (2004) (146)
Age-related decline in the in vitro and in vivo syntheses of anti-tetanus toxoid antibody in humans. (1980) (144)
Structure-based design of novel HIV-1 protease inhibitors to combat drug resistance. (2006) (139)
4′-Ethynyl Nucleoside Analogs: Potent Inhibitors of Multidrug-Resistant Human Immunodeficiency Virus Variants In Vitro (2001) (138)
Potent Inhibition of HIV-1 Replication by Novel Non-peptidyl Small Molecule Inhibitors of Protease Dimerization* (2007) (136)
Comparison of Rapid Antigen Tests for COVID-19 (2020) (133)
Altered drug sensitivity, fitness, and evolution of human immunodeficiency virus type 1 with pol gene mutations conferring multi-dideoxynucleoside resistance. (1998) (132)
HIV-1 REVERSE TRANSCRIPTASE CAN DISCRIMINATE BETWEEN TWO CONFORMATIONALLY LOCKED CARBOCYCLIC AZT TRIPHOSPHATE ANALOGUES (1998) (132)
Comparative Fitness of Multi-Dideoxynucleoside-Resistant Human Immunodeficiency Virus Type 1 (HIV-1) in an In Vitro Competitive HIV-1 Replication Assay (1999) (129)
A Potent Human Immunodeficiency Virus Type 1 Protease Inhibitor, UIC-94003 (TMC-126), and Selection of a Novel (A28S) Mutation in the Protease Active Site (2002) (128)
Enhancing Protein Backbone Binding—A Fruitful Concept for Combating Drug‐Resistant HIV† (2012) (128)
Increasing methylation of the CDKN2A gene is associated with the progression of adult T-cell leukemia. (2000) (126)
Insertion of microRNA-125b-1, a human homologue of lin-4, into a rearranged immunoglobulin heavy chain gene locus in a patient with precursor B-cell acute lymphoblastic leukemia (2005) (126)
Novel Low Molecular Weight Spirodiketopiperazine Derivatives Potently Inhibit R5 HIV-1 Infection through Their Antagonistic Effects on CCR5* (2001) (124)
PDK1 inhibition is a novel therapeutic target in multiple myeloma (2012) (119)
Structure of HIV-1 protease with KNI-272, a tight-binding transition-state analog containing allophenylnorstatine. (1995) (117)
Antibody titers against SARS-CoV-2 decline, but do not disappear for several months (2021) (117)
Changes in drug sensitivity of human immunodeficiency virus type 1 during therapy with azidothymidine, dideoxycytidine, and dideoxyinosine: an in vitro comparative study. (1993) (117)
Potential anti-AIDS drugs. 2',3'-Dideoxycytidine analogues. (1987) (111)
Antileukemic activity and mechanism of action of cordycepin against terminal deoxynucleotidyl transferase-positive (TdT+) leukemic cells. (2000) (110)
Enzymatic Characterization of Human Immunodeficiency Virus Type 1 Reverse Transcriptase Resistant to Multiple 2′,3′-Dideoxynucleoside 5′-Triphosphates (*) (1995) (105)
Mechanism of Inhibition of HIV-1 Reverse Transcriptase by 4′-Ethynyl-2-fluoro-2′-deoxyadenosine Triphosphate, a Translocation-defective Reverse Transcriptase Inhibitor* (2009) (104)
Targeted and highly efficient gene transfer into CD4+ cells by a recombinant human immunodeficiency virus retroviral vector. (1991) (103)
Chemokine and chemokine receptor gene variants and risk of non-Hodgkin's lymphoma in human immunodeficiency virus-1-infected individuals. (1999) (103)
2'-deoxy-4'-C-ethynyl-2-halo-adenosines active against drug-resistant human immunodeficiency virus type 1 variants. (2008) (101)
Missense mutation of the interleukin-12 receptor beta1 chain-encoding gene is associated with impaired immunity against Mycobacterium avium complex infection. (2001) (100)
Mutations in the receptor tyrosine kinase pathway are associated with clinical outcome in patients with acute myeloblastic leukemia harboring t(8;21)(q22;q22) (2005) (100)
2',3'-Dideoxy-2'-fluoro-ara-A. An acid-stable purine nucleoside active against human immunodeficiency virus (HIV). (1987) (100)
JE-2147: a dipeptide protease inhibitor (PI) that potently inhibits multi-PI-resistant HIV-1. (1999) (99)
Bis‐Tetrahydrofuran: a Privileged Ligand for Darunavir and a New Generation of HIV Protease Inhibitors That Combat Drug Resistance (2006) (99)
Characterization and antiviral susceptibility of SARS-CoV-2 Omicron BA.2 (2022) (98)
Activity against Human Immunodeficiency Virus Type 1, Intracellular Metabolism, and Effects on Human DNA Polymerases of 4′-Ethynyl-2-Fluoro-2′-Deoxyadenosine (2007) (98)
Decreased Stimulation of CD4+ T Cell Proliferation and IL-2 Production by Highly Enriched Populations of HIV-Infected Dendritic Cells (2003) (97)
(±)-Dioxolane-T ((±)-1-[(2β,4β)-2-(hydroxymethyl)-4-dioxolanyl]thymine): a new 2',3'-dideoxynucleoside prototype with in vitro activity against HIV (1989) (94)
Comparative inhibitory effects of suramin and other selected compounds on the infectivity and replication of human T‐cell lymphotropic virus (HTLV‐III)/lymphadenopathy‐associated virus (LAV) (1986) (93)
Macrophage inflammatory protein‐1 alpha is produced by human multiple myeloma (MM) cells and its expression correlates with bone lesions in patients with MM (2003) (89)
A randomized pilot study of alternating or simultaneous zidovudine and didanosine therapy in patients with symptomatic human immunodeficiency virus infection. (1994) (88)
In Vitro Selection of Highly Darunavir-Resistant and Replication-Competent HIV-1 Variants by Using a Mixture of Clinical HIV-1 Isolates Resistant to Multiple Conventional Protease Inhibitors (2010) (87)
Overexpression of c-Maf contributes to T-cell lymphoma in both mice and human. (2006) (86)
Multiple myeloma cells expressing low levels of CD138 have an immature phenotype and reduced sensitivity to lenalidomide (2012) (86)
A small molecule compound with an indole moiety inhibits the main protease of SARS-CoV-2 and blocks virus replication (2021) (86)
Design and synthesis of novel HIV-1 protease inhibitors incorporating oxyindoles as the P′2-ligands (2006) (85)
Broad spectrum antiretroviral activity of 2',3'-dideoxynucleosides. (1987) (84)
The A128T Resistance Mutation Reveals Aberrant Protein Multimerization as the Primary Mechanism of Action of Allosteric HIV-1 Integrase Inhibitors* (2013) (83)
Combination therapy with amprenavir, abacavir, and efavirenz in human immunodeficiency virus (HIV)-infected patients failing a protease-inhibitor regimen: pharmacokinetic drug interactions and antiviral activity. (2000) (83)
Aurintricarboxylic acid and Evans Blue represent two different classes of anionic compounds which selectively inhibit the cytopathogenicity of human T-cell lymphotropic virus type III/lymphadenopathy-associated virus. (1986) (79)
Differential influence of nucleoside analog-resistance mutations K65R and L74V on the overall mutation rate and error specificity of human immunodeficiency virus type 1 reverse transcriptase. (2000) (79)
Generation of an HLA-restricted cytotoxic T cell line reactive against cultured tumor cells from a patient infected with human T cell leukemia/lymphoma virus (1983) (77)
Human immunodeficiency virus type 1 infection of H9 cells induces increased glucose transporter expression (1996) (75)
Plasma HIV-1 viremia in HIV-1 infected individuals assessed by polymerase chain reaction. (1992) (75)
Immunoselection by natural killer cells of PIGA mutant cells missing stress-inducible ULBP. (2006) (75)
Conformationally locked nucleoside analogues. Synthesis of dideoxycarbocyclic nucleoside analogues structurally related to neplanocin C. (1994) (74)
Emergence of multi-dideoxynucleoside-resistant human immunodeficiency virus type 1 variants, viral sequence variation, and disease progression in patients receiving antiretroviral chemotherapy. (1998) (72)
Targeted therapy of human immunodeficiency virus‐related disease (1991) (69)
4′-Ethynyl-2-fluoro-2′-deoxyadenosine (EFdA) Inhibits HIV-1 Reverse Transcriptase with Multiple Mechanisms* (2014) (69)
Pharmacokinetic analysis of dextran sulfate in rats as pertains to its clinical usefulness for therapy of HIV infection. (1990) (68)
Effect of combination therapy with zidovudine and didanosine on neuropsychological functioning in patients with symptomatic HIV disease: a comparison of simultaneous and alternating regimens (1997) (68)
Cyclobut-A and cyclobut-G, carbocyclic oxetanocin analogs that inhibit the replication of human immunodeficiency virus in T cells and monocytes and macrophages in vitro (1990) (68)
Design, synthesis, and biological evaluation of the combinatorial library with a new spirodiketopiperazine scaffold. Discovery of novel potent and selective low-molecular-weight CCR5 antagonists. (2006) (68)
Potent Anti-R5 Human Immunodeficiency Virus Type 1 Effects of a CCR5 Antagonist, AK602/ONO4128/GW873140, in a Novel Human Peripheral Blood Mononuclear Cell Nonobese Diabetic-SCID, Interleukin-2 Receptor γ-Chain-Knocked-Out AIDS Mouse Model (2005) (67)
Inhibition of the infectivity and cytopathic effect of human immunodeficiency virus by water-soluble lignin in an extract of the culture medium of Lentinus edodes mycelia (LEM). (1989) (66)
Treatment of the acquired immunodeficiency syndrome (AIDS) and AIDS-related complex with a regimen of 3'-azido-2',3'-dideoxythymidine (azidothymidine or zidovudine) and acyclovir. A pilot study. (1988) (66)
Involvement of the second extracellular loop and transmembrane residues of CCR5 in inhibitor binding and HIV-1 fusion: insights into the mechanism of allosteric inhibition. (2008) (65)
Syntheses of 4‘-C-Ethynyl-β-d-arabino- and 4‘-C-Ethynyl-2‘-deoxy-β-d-ribo-pentofuranosylpyrimidines and -purines and Evaluation of Their Anti-HIV Activity (2000) (65)
Anti-retroviral therapy of human immunodeficiency virus infection: current strategies and challenges for the future. (1991) (65)
Role of the carboxy-terminal portion of the HIV-1 transmembrane protein in viral transmission and cytopathogenicity. (1989) (64)
Characterization and antiviral susceptibility of SARS-CoV-2 Omicron/BA.2 (2022) (64)
1-(2,3-Anhydro-beta-D-lyxofuranosyl)cytosine derivatives as potential inhibitors of the human immunodeficiency virus. (1988) (63)
A Novel Bis-Tetrahydrofuranylurethane-Containing Nonpeptidic Protease Inhibitor (PI), GRL-98065, Is Potent against Multiple-PI-Resistant Human Immunodeficiency Virus In Vitro (2007) (63)
Protein binding of human immunodeficiency virus protease inhibitor KNI-272 and alteration of its in vitro antiretroviral activity in the presence of high concentrations of proteins (1994) (63)
Design and synthesis of potent HIV-1 protease inhibitors incorporating hexahydrofuropyranol-derived high affinity P(2) ligands: structure-activity studies and biological evaluation. (2011) (63)
P-glycoprotein mediates efflux transport of darunavir in human intestinal Caco-2 and ABCB1 gene-transfected renal LLC-PK1 cell lines. (2009) (63)
Expression of a zinc finger gene in HTLV-I- and HTLV-II-transformed cells. (1990) (63)
Activation of the endoplasmic reticulum stress pathway is associated with survival of myeloma cells (2006) (61)
A ring-enlarged oxetanocin A analogue as an inhibitor of HIV infectivity. (1991) (60)
Dimerization of HIV-1 protease occurs through two steps relating to the mechanism of protease dimerization inhibition by darunavir (2014) (60)
An autoreactive T cell clone that can be activated to provide both helper and suppressor function. (1986) (60)
De Novo Human T-Cell Leukemia Virus Type 1 Infection of Human Lymphocytes in NOD-SCID, Common γ-Chain Knockout Mice (2006) (59)
Structural basis of HIV inhibition by translocation-defective RT inhibitor 4′-ethynyl-2-fluoro-2′-deoxyadenosine (EFdA) (2016) (59)
Clarithromycin attenuates autophagy in myeloma cells. (2010) (58)
Human monoclonal antibody directed against an envelope glycoprotein of human T-cell leukemia virus type I. (1986) (58)
The National Cancer Institute phase I study of 2',3'-dideoxyinosine administration in adults with AIDS or AIDS-related complex: analysis of activity and toxicity profiles. (1990) (58)
Pharmacological inhibition of in vitro infectivity of human T lymphotropic virus type I. (1987) (58)
FoxP3+ regulatory T cells are distinct from leukemia cells in HTLV‐1–associated adult T‐cell leukemia (2009) (58)
Dual mutations in the AML1 and FLT3 genes are associated with leukemogenesis in acute myeloblastic leukemia of the M0 subtype (2003) (58)
Adenallene and cytallene: acyclic-nucleoside analogues that inhibit replication and cytopathic effect of human immunodeficiency virus in vitro. (1988) (58)
Synthesis of phosphorothioate analogues of oligodeoxyribonucleotides and their antiviral activity against human immunodeficiency virus (HIV). (1988) (57)
Shikonin, dually functions as a proteasome inhibitor and a necroptosis inducer in multiple myeloma cells (2014) (57)
Altered HIV-1 Gag Protein Interactions with Cyclophilin A (CypA) on the Acquisition of H219Q and H219P Substitutions in the CypA Binding Loop* (2006) (57)
Potential anti-AIDS drugs. Lipophilic, adenosine deaminase-activated prodrugs. (1991) (57)
Vertical transmission of human immunodeficiency virus type 1: autologous neutralizing antibody, virus load, and virus phenotype. (1995) (56)
Quantitative analysis of HIV-1 proviral DNA in peripheral blood mononuclear cells from patients with AIDS or ARC: decrease of proviral DNA content following treatment with 2',3'-dideoxyinosine (ddI). (1990) (56)
Comparative enzymatic study of HIV-1 reverse transcriptase resistant to 2',3'-dideoxynucleotide analogs using the single-nucleotide incorporation assay. (1997) (56)
Design and Development of Highly Potent HIV-1 Protease Inhibitors with a Crown-Like Oxotricyclic Core as the P2-Ligand To Combat Multidrug-Resistant HIV Variants. (2017) (55)
Down-regulation of PU.1 by methylation of distal regulatory elements and the promoter is required for myeloma cell growth. (2007) (55)
c-Maf Expression in Angioimmunoblastic T-cell Lymphoma (2007) (55)
Design of HIV-1 protease inhibitors with pyrrolidinones and oxazolidinones as novel P1'-ligands to enhance backbone-binding interactions with protease: synthesis, biological evaluation, and protein-ligand X-ray studies. (2009) (54)
The Impact of Multidideoxynucleoside Resistance-Conferring Mutations in Human Immunodeficiency Virus Type 1 Reverse Transcriptase on Polymerase Fidelity and Error Specificity (1998) (54)
Inhibition of duck hepatitis B virus replication by 2',3'-dideoxycytidine. A potent inhibitor of reverse transcriptase. (1989) (54)
Age-related changes in suppressor functions of human T cells. (1979) (53)
Lipophilic halogenated congeners of 2',3'-dideoxypurine nucleosides active against human immunodeficiency virus in vitro. (1990) (53)
Characterization of a new SARS-CoV-2 variant that emerged in Brazil (2021) (53)
Expression of Bcl-2 family of proteins in fresh myeloma cells (1998) (52)
Synthesis and anti-HIV activity of isonucleosides. (1992) (52)
Antiretroviral Therapy in AIDS (1990) (51)
Transformation and cytopathogenic effect in an immune human T-cell clone infected by HTLV-I. (1984) (50)
Functional properties of antigen-specific T cells infected by human T-cell leukemia-lymphoma virus (HTLV-I). (1984) (50)
Structure-based design: synthesis and biological evaluation of a series of novel cycloamide-derived HIV-1 protease inhibitors. (2005) (49)
Development of protease inhibitors and the fight with drug-resistant HIV-1 variants. (2008) (48)
Potent Activity of a Nucleoside Reverse Transcriptase Inhibitor, 4′-Ethynyl-2-Fluoro-2′-Deoxyadenosine, against Human Immunodeficiency Virus Type 1 Infection in a Model Using Human Peripheral Blood Mononuclear Cell-Transplanted NOD/SCID Janus Kinase 3 Knockout Mice (2009) (48)
Relationship between an effective dose of imatinib, body surface area, and trough drug levels in patients with chronic myeloid leukemia (2009) (48)
Synthesis of acyloxyalkyl acylphosphonates as potential prodrugs of the antiviral, trisodium phosphonoformate (foscarnet sodium) (1989) (48)
Overview of the preclinical development of an antiretroviral drug, 2',3'-dideoxyinosine. (1990) (47)
A conformationally locked analogue of the anti-HIV agent stavudine. An important correlation between pseudorotation and maximum amplitude. (2003) (47)
Indium-mediated atom-transfer and reductive radical cyclizations of iodoalkynes: synthesis and biological evaluation of HIV-protease inhibitors. (2004) (47)
Response of Simian Immunodeficiency Virus to the Novel Nucleoside Reverse Transcriptase Inhibitor 4′-Ethynyl-2-Fluoro-2′-Deoxyadenosine In Vitro and In Vivo (2012) (47)
A high proportion of early response genes are constitutively activated in T cells by HTLV-I. (1992) (46)
The current status of, and challenges in, the development of CCR5 inhibitors as therapeutics for HIV-1 infection. (2004) (46)
Hypoxia reduces CD138 expression and induces an immature and stem cell-like transcriptional program in myeloma cells (2013) (46)
Age-related decrease in frequencies of B-cell precursors and specific helper T cells involved in the IgG anti-tetanus toxoid antibody production in humans. (1982) (46)
2'-Fluoro-2',3'-dideoxyarabinosyladenine: a metabolically stable analogue of the antiretroviral agent 2',3'-dideoxyadenosine. (1990) (46)
In vitro inhibition of the infectivity and replication of human immunodeficiency virus type 1 by combination of antiretroviral 2',3'-dideoxynucleosides and virus-binding inhibitors (1990) (45)
Overcoming HIV drug resistance through rational drug design based on molecular, biochemical, and structural profiles of HIV resistance (2006) (45)
Quantitative analysis of viral burden in tissues from adults and children with symptomatic human immunodeficiency virus type 1 infection assessed by polymerase chain reaction. (1994) (45)
Potential of 4′-C-Substituted Nucleosides for the Treatment of HIV-1 (2004) (44)
Identification of a Key Target Sequence To Block Human Immunodeficiency Virus Type 1 Replication within thegag-pol Transframe Domain (2000) (44)
HIV-1 acquires resistance to two classes of antiviral drugs through homologous recombination. (1997) (43)
Decreased susceptibility of leukemic cells with PIG-A mutation to natural killer cells in vitro. (2002) (43)
Probing Multidrug‐Resistance and Protein–Ligand Interactions with Oxatricyclic Designed Ligands in HIV‐1 Protease Inhibitors (2010) (43)
Spirodiketopiperazine-based CCR5 antagonists: Lead optimization from biologically active metabolite. (2007) (42)
In vitro selection and molecular characterization of human immunodeficiency virus type 1 with reduced sensitivity to 9-[2-(phosphonomethoxy)ethyl]adenine (PMEA). (1996) (42)
Initial Clinical Experience with Dideoxynucleosides as Single Agents and in Combination Therapy (1990) (42)
Genetic evidence of transmission of human T cell lymphotropic virus type 1 between spouses. (2002) (42)
Highly potent HIV-1 protease inhibitors with novel tricyclic P2 ligands: design, synthesis, and protein-ligand X-ray studies. (2013) (42)
Switching Tenofovir/Emtricitabine plus Lopinavir/r to Raltegravir plus Darunavir/r in Patients with Suppressed Viral Load Did Not Result in Improvement of Renal Function but Could Sustain Viral Suppression: A Randomized Multicenter Trial (2013) (42)
CCR5 inhibitors: emergence, success, and challenges (2012) (41)
Design, synthesis, protein-ligand X-ray structure, and biological evaluation of a series of novel macrocyclic human immunodeficiency virus-1 protease inhibitors to combat drug resistance. (2009) (41)
GRL-0920, an Indole Chloropyridinyl Ester, Completely Blocks SARS-CoV-2 Infection (2020) (41)
Association of SLCO1B3 polymorphism with intracellular accumulation of imatinib in leukocytes in patients with chronic myeloid leukemia. (2011) (41)
GRL-02031, a Novel Nonpeptidic Protease Inhibitor (PI) Containing a Stereochemically Defined Fused Cyclopentanyltetrahydrofuran Potent against Multi-PI-Resistant Human Immunodeficiency Virus Type 1 In Vitro (2008) (40)
Prediction of Potency of Protease Inhibitors Using Free Energy Simulations with Polarizable Quantum Mechanics-Based Ligand Charges and a Hybrid Water Model (2009) (40)
2′-Deoxy-4′-C-Ethynyl-2-Fluoroadenosine: A Nucleoside Reverse Transcriptase Inhibitor with Highly Potent Activity Against Wide Spectrum of HIV-1 Strains, Favorable Toxic Profiles, and Stability in Plasma (2007) (40)
Successful treatment of TAFRO syndrome, a variant type of multicentric Castleman disease with thrombotic microangiopathy, with anti-IL-6 receptor antibody and steroids (2016) (39)
In Vitro Induction of Human Immunodeficiency Virus Type 1 Variants Resistant to Phosphoralaninate Prodrugs of Z-Methylenecyclopropane Nucleoside Analogues (1999) (38)
IDH1 and IDH2 mutations confer an adverse effect in patients with acute myeloid leukemia lacking the NPM1 mutation (2013) (38)
Flexible cyclic ethers/polyethers as novel P2-ligands for HIV-1 protease inhibitors: design, synthesis, biological evaluation, and protein-ligand X-ray studies. (2008) (38)
Differences in the interaction of HIV-1 and HIV-2 with CD4. (1990) (37)
Conserved Cysteines of the Human Immunodeficiency Virus Type 1 Protease Are Involved in Regulation of Polyprotein Processing and Viral Maturation of Immature Virions (1999) (37)
Establishment and characterization of adenosine deaminase-deficient human T cell lines. (1989) (37)
4′‐modified nucleoside analogs: Potent inhibitors active against entecavir‐resistant hepatitis B virus (2015) (37)
Lactate, a putative survival factor for myeloma cells, is incorporated by myeloma cells through monocarboxylate transporters 1 (2015) (37)
A novel highly quantitative and reproducible assay for the detection of anti-SARS-CoV-2 IgG and IgM antibodies (2021) (36)
Design, Efficient Synthesis, and Anti‐HIV Activity of 4′‐C‐Cyano‐ and 4′‐C‐Ethynyl‐2′‐deoxy Purine Nucleosides (2004) (36)
Mechanism of Darunavir (DRV)’s High Genetic Barrier to HIV-1 Resistance: A Key V32I Substitution in Protease Rarely Occurs, but Once It Occurs, It Predisposes HIV-1 To Develop DRV Resistance (2018) (36)
Alterations in cytotoxic and helper T cell function after infection of T cell clones with human T cell leukemia virus, type I. (1986) (36)
PU.1 is a potent tumor suppressor in classical Hodgkin lymphoma cells. (2013) (36)
A 4'-C-ethynyl-2',3'-dideoxynucleoside analogue highlights the role of the 3'-OH in anti-HIV active 4'-C-ethynyl-2'-deoxy nucleosides. (2004) (36)
Escherichia coli mediated biosynthesis and in vitro anti-HIV activity of lipophilic 6-halo-2',3'-dideoxypurine nucleosides. (1991) (36)
PERIPHERAL HEMOPHAGOCYTOSIS: AN EARLY INDICATOR OF ADVANCED SYSTEMIC INFLAMMATORY RESPONSE SYNDROME/HEMOPHAGOCYTIC SYNDROME (2006) (35)
Neutralization of SARS-CoV-2 with IgG from COVID-19-convalescent plasma (2021) (35)
Analysis of T cell responses to the β2-glycoprotein I-derived peptide library in patients with anti-β2-glycoprotein I antibody-associated autoimmunity (2000) (35)
High-level resistance to zidovudine but not to zalcitabine or didanosine in human immunodeficiency virus from children receiving antiretroviral therapy. (1993) (35)
Inhibition of infectivity and replication of HIV-2 and SIV in helper T-cells by 2',3'-dideoxynucleosides in vitro. (1988) (35)
Indole Chloropyridinyl Ester-Derived SARS-CoV-2 3CLpro Inhibitors: Enzyme Inhibition, Antiviral Efficacy, Structure–Activity Relationship, and X-ray Structural Studies (2021) (35)
A pilot study of 2′,3′‐dideoxyinosine for the treatment of chronic hepatitis B (1992) (35)
Correlates of Neutralizing/SARS-CoV-2-S1-binding Antibody Response with Adverse Effects and Immune Kinetics in BNT162b2-Vaccinated Individuals (2021) (35)
Loss of Protease Dimerization Inhibition Activity of Darunavir Is Associated with the Acquisition of Resistance to Darunavir by HIV-1 (2011) (35)
Comparative analysis of ER stress response into HIV protease inhibitors: lopinavir but not darunavir induces potent ER stress response via ROS/JNK pathway. (2013) (34)
Coronavirus Disease 2019 (COVID-19) Breakthrough Infection and Post-Vaccination Neutralizing Antibodies Among Healthcare Workers in a Referral Hospital in Tokyo: A Case-Control Matching Study (2021) (34)
(Z)- and (E)-[2-Fluoro-2-(hydroxymethyl)cyclopropylidene]methylpurines and -pyrimidines, a new class of methylenecyclopropane analogues of nucleosides: synthesis and antiviral activity. (2004) (34)
Hypersusceptibility mechanism of Tenofovir-resistant HIV to EFdA (2013) (34)
Inhibition of HIV-1 replication by a peptide dimerization inhibitor of HIV-1 protease. (2006) (34)
Central nervous system targeting of 2',3'-dideoxyinosine via adenosine deaminase-activated 6-halo-dideoxypurine prodrugs (1992) (34)
Combination of a Latency-Reversing Agent With a Smac Mimetic Minimizes Secondary HIV-1 Infection in vitro (2018) (33)
Reduction of peptide character of HIV protease inhibitors that exhibit nanomolar potency against multidrug resistant HIV-1 strains. (2003) (33)
Hematologic effects of AIDS therapies. (1991) (32)
Pathways for the emergence of multi-dideoxynucleoside-resistant HIV-1 variants (2003) (32)
Lipophilic, acid-stable, adenosine deaminase-activated anti-HIV prodrugs for central nervous system delivery. 3. 6-Amino prodrugs of 2'-beta-fluoro-2',3'-dideoxyinosine. (1995) (32)
Potent Synergistic Anti-Human Immunodeficiency Virus (HIV) Effects Using Combinations of the CCR5 Inhibitor Aplaviroc with Other Anti-HIV Drugs (2008) (32)
A novel central nervous system-penetrating protease inhibitor overcomes human immunodeficiency virus 1 resistance with unprecedented aM to pM potency (2017) (32)
Down-Regulation of CD98 in Melphalan-Resistant Myeloma Cells with Reduced Drug Uptake (2000) (32)
Non-Cleavage Site Gag Mutations in Amprenavir-Resistant Human Immunodeficiency Virus Type 1 (HIV-1) Predispose HIV-1 to Rapid Acquisition of Amprenavir Resistance but Delay Development of Resistance to Other Protease Inhibitors (2009) (32)
Prediction of Potency of Protease Inhibitors Using Free Energy Simulations with Polarizable Quantum Mechanics‐Based Ligand Charges and a Hybrid Water Model. (2010) (32)
Effect of translocation defective reverse transcriptase inhibitors on the activity of N348I, a connection subdomain drug resistant HIV-1 reverse transcriptase mutant. (2012) (31)
Design of HIV-1 protease inhibitors with C3-substituted hexahydrocyclopentafuranyl urethanes as P2-ligands: synthesis, biological evaluation, and protein-ligand X-ray crystal structure. (2011) (31)
Design of Highly Potent, Dual‐Acting and Central‐Nervous‐System‐Penetrating HIV‐1 Protease Inhibitors with Excellent Potency against Multidrug‐Resistant HIV‐1 Variants (2018) (31)
High frequency of IKZF1 genetic alterations in adult patients with B‐cell acute lymphoblastic leukemia (2013) (31)
In Vitro Anti-Human Immunodeficiency Virus Activities ofZ- and E-Methylenecyclopropane Nucleoside Analogues and Their Phosphoro-l-Alaninate Diesters (1999) (30)
The absence of the p15INK4B gene alterations in adult patients with precursor B‐cell acute lymphoblastic leukaemia is a favourable prognostic factor (2002) (30)
Induction of cell cycle arrest and apoptosis in myeloma cells by cepharanthine, a biscoclaurine alkaloid. (2008) (30)
The sugar ring conformation of 4'-ethynyl-2-fluoro-2'-deoxyadenosine and its recognition by the polymerase active site of HIV reverse transcriptase. (2011) (30)
Delayed Emergence of HIV-1 Variants Resistant to 4′-Ethy Nyl-2-Fluoro-2′-Deoxyadenosine: Comparative Sequential Passage Study with Lamivudine, Tenofovir, Emtricitabine and BMS-986001 (2014) (30)
Dehydroxymethylepoxyquinomicin, a novel nuclear factor-κB inhibitor, induces apoptosis in multiple myeloma cells in an IκBα-independent manner (2005) (29)
Frequent detection of T cells with mutations of the hypoxanthine-guanine phosphoribosyl transferase gene in patients with paroxysmal nocturnal hemoglobinuria. (2002) (29)
Effects of Substitutions at the 4′ and 2 Positions on the Bioactivity of 4′-Ethynyl-2-Fluoro-2′-Deoxyadenosine (2013) (29)
P2′ Benzene Carboxylic Acid Moiety Is Associated with Decrease in Cellular Uptake: Evaluation of Novel Nonpeptidic HIV-1 Protease Inhibitors Containing P2 bis-Tetrahydrofuran Moiety (2013) (29)
(R)-(-)- and (S)-(+)-adenallene: synthesis, absolute configuration, enantioselectivity of antiretroviral effect, and enzymic deamination. (1992) (29)
Synthesis and antiviral activities of carbocyclic oxetanocin analogues. (1990) (28)
Novel HIV-1 Protease Inhibitors (PIs) Containing a Bicyclic P2 Functional Moiety, Tetrahydropyrano-Tetrahydrofuran, That Are Potent against Multi-PI-Resistant HIV-1 Variants (2011) (27)
Clinical and basic advances in the antiretroviral therapy of human immunodeficiency virus infection. (1989) (27)
In vitro transdifferentiation of adult bone marrow Sca-1+ cKit- cells cocultured with fetal liver cells into hepatic-like cells without fusion. (2006) (27)
In vitro induction of human immunodeficiency virus type 1 variants resistant to 2'-beta-Fluoro-2',3'-dideoxyadenosine (1997) (26)
Design, synthesis, and X-ray structure of substituted bis-tetrahydrofuran (bis-THF)-derived potent HIV-1 protease inhibitors (2011) (26)
Design and Synthesis of Highly Potent HIV-1 Protease Inhibitors Containing Tricyclic Fused Ring Systems as Novel P2 Ligands: Structure-Activity Studies, Biological and X-ray Structural Analysis. (2018) (26)
Imatinib mesylate for refractory acute myeloblastic leukemia harboring inv(16) and a C-KIT exon 8 mutation (2005) (26)
Phosphodiester amidates of allenic nucleoside analogues: anti-HIV activity and possible mechanism of action. (1996) (26)
A family harboring a germ‐line N‐terminal C/EBPα mutation and development of acute myeloid leukemia with an additional somatic C‐terminal C/EBPα mutation (2009) (25)
Synthesis, absolute configuration, and enantioselectivity of antiretroviral effect of (R)-(-)- and (S)-(+)-cytallene. Lipase-catalyzed enantioselective acylations of (+/-)-N4-acylcytallenes. (1995) (25)
Sustaining containment of COVID-19: global sharing for pandemic response. (2020) (25)
Insights into the Mechanism of Inhibition of CXCR4: Identification of Piperidinylethanamine Analogs as Anti-HIV-1 Inhibitors (2015) (25)
Mutation in the RNA binding protein TIS11D/ZFP36L2 is associated with the pathogenesis of acute leukemia. (2010) (25)
Interactions of conformationally biased north and south 2'-fluoro-2', 3'-dideoxynucleoside 5'-triphosphates with the active site of HIV-1 reverse transcriptase. (2000) (24)
Correlates of neutralizing/SARS-CoV-2-S1-binding antibody response with adverse effects and immune kinetics in BNT162b2-vaccinated individuals (2021) (24)
Torsades de pointes upon fluconazole administration in a patient with acute myeloblastic leukemia (2006) (24)
A nitric oxide synthase inhibitor, NG‐nitro‐l‐arginine‐methyl‐ester, exerts potent antiangiogenic effects on plasmacytoma in a newly established multiple myeloma severe combined immunodeficient mouse model (2003) (24)
p15 mRNA expression detected by real-time quantitative reverse transcriptase-polymerase chain reaction correlates with the methylation density of the gene in adult acute leukemia. (2005) (24)
Pathophysiologic analysis of peripheral blood lymphocytes from patients with primary immunodeficiency. I. Ig synthesis by peripheral blood lymphocytes stimulated with either pokeweed mitogen or Epstein-Barr virus in vitro. (1981) (24)
Detection of inducible nitric oxide synthase (iNOS) mRNA by RT-PCR in ATL patients and HTLV-I infected cell lines: clinical features and apoptosis by NOS inhibitor (1999) (24)
GRL-0519, a Novel Oxatricyclic Ligand-Containing Nonpeptidic HIV-1 Protease Inhibitor (PI), Potently Suppresses Replication of a Wide Spectrum of Multi-PI-Resistant HIV-1 Variants In Vitro (2013) (24)
1-(3-cyano-2,3-dideoxy-beta-D-erythro-pentofuranosyl)thymine (cyanothymidine): synthesis and antiviral evaluation against human immunodeficiency virus. (1989) (24)
Chemistry and anti-HIV properties of 2'-fluoro-2',3'-dideoxyarabinofuranosylpyrimidines. (1992) (24)
Resistance profile of a neutralizing anti-HIV monoclonal antibody, KD-247, that shows favourable synergism with anti-CCR5 inhibitors (2006) (24)
Increase of C1q biosynthesis in brain microglia and macrophages during lentivirus infection in the rhesus macaque is sensitive to antiretroviral treatment with 6-chloro-2′,3′-dideoxyguanosine (2005) (24)
Mechanism of Interaction of Human Mitochondrial DNA Polymerase γ with the Novel Nucleoside Reverse Transcriptase Inhibitor 4′-Ethynyl-2-Fluoro-2′-Deoxyadenosine Indicates a Low Potential for Host Toxicity (2011) (24)
Acute promyelocytic leukemia harboring a STAT5B‐RARA fusion gene and a G596V missense mutation in the STAT5B SH2 domain of the STAT5B‐RARA (2009) (23)
Brain virus burden and indoleamine‐2,3‐dioxygenase expression during lentiviral infection of rhesus monkey are concomitantly lowered by 6‐chloro‐2′,3′‐dideoxyguanosine (2004) (23)
Seroprevalence of antibodies against SARS-CoV-2 in a large national hospital and affiliated facility in Tokyo, Japan (2021) (22)
GRL-04810 and GRL-05010, Difluoride-Containing Nonpeptidic HIV-1 Protease Inhibitors (PIs) That Inhibit the Replication of Multi-PI-Resistant HIV-1 In Vitro and Possess Favorable Lipophilicity That May Allow Blood-Brain Barrier Penetration (2013) (22)
Challenges in the therapy of HIV infection. (1993) (22)
Potentiation of The Anti-HIV Activity of Zalcitabine and Lamivudine by a CTP Synthase Inhibitor, 3-Deazauridine (2000) (22)
Evidence for the failure of IgA specific T helper activity in a patient with immunodeficiency with hyper IgM. (1979) (22)
Benzolactam-related compounds promote apoptosis of HIV-infected human cells via protein kinase C–induced HIV latency reversal (2018) (21)
2',3'-Dideoxyadenosine is selectively toxic for TdT-positive cells. (1988) (21)
Approaches toward the optimization of CNS uptake of anti-AIDS agents (1992) (21)
Loss of the Protease Dimerization Inhibition Activity of Tipranavir (TPV) and Its Association with the Acquisition of Resistance to TPV by HIV-1 (2012) (21)
Acid-Stable 2′-Fluoro Purine Dideoxynucleosides as Active Agents Against HIV. (1990) (21)
Identification of Amino Acid Residues Critical for LD78β, a Variant of Human Macrophage Inflammatory Protein-1α, Binding to CCR5 and Inhibition of R5 Human Immunodeficiency Virus Type 1 Replication* (2002) (21)
Monitoring the activity of antiviral therapy for HIV infection using a polymerase chain reaction method coupled with reverse transcription (1993) (21)
Novel Protease Inhibitors (PIs) Containing Macrocyclic Components and 3(R),3a(S),6a(R)-bis-Tetrahydrofuranylurethane That Are Potent against Multi-PI-Resistant HIV-1 Variants In Vitro (2010) (21)
Design and Synthesis of Potent HIV-1 Protease Inhibitors Containing Bicyclic Oxazolidinone Scaffold as the P2 Ligands: Structure-Activity Studies and Biological and X-ray Structural Studies. (2018) (20)
Unsaturated acyclic analogues of 2'-deoxyadenosine and thymidine containing fluorine: synthesis and biological activity. (1995) (20)
Design of gem‐Difluoro‐bis‐Tetrahydrofuran as P2 Ligand for HIV‐1 Protease Inhibitors to Improve Brain Penetration: Synthesis, X‐ray Studies, and Biological Evaluation (2015) (20)
Two cases showing clonal progression with full evolution from aplastic anemia-paroxysmal nocturnal hemoglobinuria syndrome to myelodysplastic syndromes and leukemia. (2000) (19)
9-{[3-fluoro-2-(hydroxymethyl)cyclopropylidene]methyl}adenines and -guanines. Synthesis and antiviral activity of all stereoisomers1. (2006) (19)
Phenotypic and Genotypic Comparisons of Human T-Cell Leukemia Virus Type 1 Reverse Transcriptases from Infected T-Cell Lines and Patient Samples (2007) (19)
Cross-linking HLA-DR molecules on Th1 cells induces anergy in association with increased level of cyclin-dependent kinase inhibitor p27(Kip1). (2002) (19)
Expression of PRAD1/cyclin D1 in plasma cell malignancy: incidence and prognostic aspects (1999) (19)
PU.1 acts as tumor suppressor for myeloma cells through direct transcriptional repression of IRF4 (2017) (19)
HIV-1 protease does not play a critical role in the early stages of HIV-1 infection. (1997) (19)
Five-year follow-up of a phase I study of didanosine in patients with advanced human immunodeficiency virus infection. (1995) (19)
The High Genetic Barrier of EFdA/MK-8591 Stems from Strong Interactions with the Active Site of Drug-Resistant HIV-1 Reverse Transcriptase. (2018) (19)
Evidence for a malignant proliferation of IgE-class specific helper T cells in a patient with Sézary syndrome exhibiting massive hyperimmunoglobulinemia E. (1983) (18)
Successful Treatment of Cisplatin Overdose with Plasma Exchange (2010) (18)
Novel patterns of nevirapine resistance-associated mutations of human immunodeficiency virus type 1 in treatment-naïve patients. (2004) (18)
Combined anti-tumor necrosis factor-α therapy and DMARD therapy in rheumatoid arthritis patients reduces inflammatory gene expression in whole blood compared to DMARD therapy alone (2012) (18)
Configuration and expression of the T cell receptor beta chain gene in human T-lymphotrophic virus I-infected cells (1986) (18)
PU.1 induces apoptosis in myeloma cells through direct transactivation of TRAIL (2009) (18)
Structure-based design, synthesis, X-ray studies, and biological evaluation of novel HIV-1 protease inhibitors containing isophthalamide-derived P2-ligands. (2015) (18)
Structure-based design of potent HIV-1 protease inhibitors with modified P1-biphenyl ligands: synthesis, biological evaluation, and enzyme-inhibitor X-ray structural studies. (2015) (18)
Rituximab Monotherapy and Rituximab-Containing Chemotherapy Were Effective for Paraneoplastic Pemphigus Accompanying Follicular Lymphoma, but not for Subsequent Bronchiolitis Obliterans. (2015) (17)
HIV-I infection and cellular metabolism. (1996) (17)
Substituent effects on P2-cyclopentyltetrahydrofuranyl urethanes: design, synthesis, and X-ray studies of potent HIV-1 protease inhibitors. (2012) (17)
A JAK2-V617F activating mutation in addition to KIT and FLT3 mutations is associated with clinical outcome in patients with t(8;21)(q22;q22) acute myeloid leukemia (2009) (17)
Removal of human immunodeficiency virus type 1 (HIV-1) protease inhibitors from preparations of immature HIV-1 virions does not result in an increase in infectivity or the appearance of mature morphology (1997) (17)
Concurrent transcriptional deregulation of AML1/RUNX1 and GATA factors by the AML1-TRPS1 chimeric gene in t(8;21)(q24;q22) acute myeloid leukemia. (2007) (17)
Novel p97/VCP inhibitor induces endoplasmic reticulum stress and apoptosis in both bortezomib‐sensitive and ‐resistant multiple myeloma cells (2019) (17)
A novel type of factor XI deficiency showing compound genetic abnormalities: a nonsense mutation and an impaired transcription. (2000) (17)
Pharmacokinetics of dideoxypurine nucleoside analogs in plasma and cerebrospinal fluid of rhesus monkeys (1995) (17)
Low-dose cytarabine and aclarubicin in combination with granulocyte colony-stimulating factor for elderly patients with previously untreated acute myeloid leukemia. (2010) (17)
A Conserved Hydrogen-Bonding Network of P2 bis-Tetrahydrofuran-Containing HIV-1 Protease Inhibitors (PIs) with a Protease Active-Site Amino Acid Backbone Aids in Their Activity against PI-Resistant HIV (2014) (16)
Telling the Truth to Cancer Patients and Patients with HIV‐1 Infection in Japan (1997) (16)
Evaluation of Combinations of 4′-Ethynyl-2-Fluoro-2′-Deoxyadenosine with Clinically Used Antiretroviral Drugs (2013) (16)
Purified GPI-anchored CD4DAF as a receptor for HIV-mediated gene transfer. (1994) (16)
Biochemical, inhibition and inhibitor resistance studies of xenotropic murine leukemia virus-related virus reverse transcriptase (2011) (16)
Abacavir/lamivudine versus tenofovir/emtricitabine with atazanavir/ritonavir for treatment-naive Japanese patients with HIV-1 infection: a randomized multicenter trial. (2013) (16)
Excessive fibrinolysis in AL-amyloidosis is induced by urokinae-type plasminogen activator from bone marrow plasma cells (2009) (16)
Balancing Antiviral Potency and Host Toxicity: Identifying a Nucleotide Inhibitor with an Optimal Kinetic Phenotype for HIV-1 Reverse Transcriptase (2012) (15)
Probing the molecular mechanism of action of the HIV-1 reverse transcriptase inhibitor 4'-ethynyl-2-fluoro-2'-deoxyadenosine (EFdA) using pre-steady-state kinetics. (2014) (15)
Human T lymphotropic virus I infection deregulates surface expression of the transferrin receptor. (1988) (15)
A novel FLT3 activation loop mutation N841K in acute myeloblastic leukemia (2005) (15)
Seroprevalence of SARS-CoV-2 antibodies in a national hospital and affiliated facility after the second epidemic wave of Japan (2021) (15)
Pharmacological inhibition of infectivity of HTLV-III in vitro. (1985) (15)
Design and synthesis of potent macrocyclic HIV-1 protease inhibitors involving P1-P2 ligands. (2014) (15)
Potent HIV-1 protease inhibitors incorporating meso-bicyclic urethanes as P2-ligands: structure-based design, synthesis, biological evaluation and protein-ligand X-ray studies. (2008) (14)
Identification of a novel long-acting 4'-modified nucleoside reverse transcriptase inhibitor against HBV. (2020) (14)
Darunavir, a New PI with Dual Mechanism: From a Novel Drug Design Concept to New Hope against Drug‐Resistant HIV (2011) (14)
Preformulation studies of EFdA, a novel nucleoside reverse transcriptase inhibitor for HIV prevention (2014) (14)
Spirodiketopiperazine-based CCR5 antagonists: Improvement of their pharmacokinetic profiles. (2010) (14)
Determination of 2′-β-fluoro-2′,3′-dideoxyadenosine, an experimental anti-AIDS drug, in human plasma by high-performance liquid chromatography (1998) (14)
Design of novel HIV-1 protease inhibitors incorporating isophthalamide-derived P2-P3 ligands: Synthesis, biological evaluation and X-ray structural studies of inhibitor-HIV-1 protease complex. (2017) (14)
Analysis of T cell responses to the beta 2-glycoprotein I-derived peptide library in patients with anti-beta 2-glycoprotein I antibody-associated autoimmunity. (2000) (14)
3-Hydroxypyrimidine-2,4-Diones as Novel Hepatitis B Virus Antivirals Targeting the Viral Ribonuclease H (2017) (14)
Discovery of orally available spirodiketopiperazine-based CCR5 antagonists. (2010) (14)
Infection of human T lymphotropic virus-I-specific immune T cell clones by human T lymphotropic virus-I. (1986) (13)
Activation and function of an autoreactive T cell clone with dual immunoregulatory activity. (1988) (13)
Fight against COVID-19 but avoid disruption of services for other communicable diseases (CDs) and noncommunicable diseases (NCDs). (2020) (13)
Challenges in the therapy of HIV infection. (1993) (13)
TRAIL produced from multiple myeloma cells is associated with osteolytic markers. (2011) (13)
Complete nucleotide sequences of functional clones of the virus associated with the acquired immunodeficiency syndrome, HTLV-III/LAV. (1987) (13)
Dehydroxymethylepoxyquinomicin, a novel nuclear factor-kappaB inhibitor, induces apoptosis in multiple myeloma cells in an IkappaBalpha-independent manner. (2005) (13)
Combined use of bortezomib, cyclophosphamide, and dexamethasone induces favorable hematological and organ responses in Japanese patients with amyloid light-chain amyloidosis: a single-institution retrospective study (2015) (13)
Simultaneous occurrence of acute myelogenous leukaemia and multiple myeloma without previous chemotherapy. (2009) (13)
Bis‐Tetrahydrofuran: A Privileged Ligand for Darunavir and a New Generation of HIV Protease Inhibitors that Combat Drug Resistance. (2006) (13)
GRL-09510, a Unique P2-Crown-Tetrahydrofuranylurethane -Containing HIV-1 Protease Inhibitor, Maintains Its Favorable Antiviral Activity against Highly-Drug-Resistant HIV-1 Variants in vitro (2017) (13)
SARS-CoV-2 specific T cell and humoral immune responses upon vaccination with BNT162b2: a 9 months longitudinal study (2022) (12)
A Novel Tricyclic Ligand-Containing Nonpeptidic HIV-1 Protease Inhibitor, GRL-0739, Effectively Inhibits the Replication of Multidrug-Resistant HIV-1 Variants and Has a Desirable Central Nervous System Penetration Property In Vitro (2015) (12)
C-5-Modified Tetrahydropyrano-Tetrahydofuran-Derived Protease Inhibitors (PIs) Exert Potent Inhibition of the Replication of HIV-1 Variants Highly Resistant to Various PIs, including Darunavir (2015) (12)
Structural features in common of HBV and HIV-1 resistance against chirally-distinct nucleoside analogues entecavir and lamivudine (2020) (12)
Synthesis and biological evaluation of novel allophenylnorstatine-based HIV-1 protease inhibitors incorporating high affinity P2-ligands. (2010) (12)
2′‐Deoxy‐4′‐C‐ethynyl‐2‐fluoroadenosine: A Nucleoside Reverse Transcriptase Inhibitor with Highly Potent Activity Against Wide Spectrum of HIV‐1 Strains, Favorable Toxic Profiles, and Stability in Plasma (2008) (12)
Structure-Based Design of Highly Potent HIV-1 Protease Inhibitors Containing New Tricyclic Ring P2-Ligands: Design, Synthesis, Biological, and X-ray Structural Studies. (2020) (12)
Potent HIV‐1 Protease Inhibitors Containing Carboxylic and Boronic Acids: Effect on Enzyme Inhibition and Antiviral Activity and Protein‐Ligand X‐ray Structural Studies (2019) (12)
Design of HIV-1 Protease Inhibitors with Amino-bis-tetrahydrofuran Derivatives as P2-Ligands to Enhance Backbone-Binding Interactions: Synthesis, Biological Evaluation, and Protein-Ligand X-ray Studies. (2015) (12)
Restoration of immune surface molecules in Kaposi sarcoma-associated herpesvirus infected cells by lenalidomide and pomalidomide. (2017) (12)
Inhibition of human immunodeficiency virus reverse transcriptase by synadenol triphosphate and its E-isomer. (2003) (12)
HIV-Associated Neurocognitive Disorder (HAND) and the Prospect of Brain-Penetrating Protease Inhibitors for Antiretroviral Treatment. (2017) (12)
Probing Lipophilic Adamantyl Group as the P1-Ligand for HIV-1 Protease Inhibitors: Design, Synthesis, Protein X-ray Structural Studies, and Biological Evaluation. (2016) (12)
Successful treatment with rituximab and thalidomide of POEMS syndrome associated with Waldenstrom macroglobulinemia (2010) (12)
Design and synthesis of stereochemically defined novel spirocyclic P2-ligands for HIV-1 protease inhibitors. (2008) (11)
Successful treatment of Aspergillus liver abscesses in a patient with acute monoblastic leukemia using combination antifungal therapy including micafungin as a key drug (2010) (11)
Anti-HIV nucleosides: past, present and future. (1997) (11)
Recent Drug Development and Medicinal Chemistry Approaches for the Treatment of SARS‐CoV‐2 and Covid‐19 (2022) (11)
Increase of the adenallene anti-HIV activity in cell culture using its bis(tBuSATE) phosphotriester derivative. (2002) (11)
HIV-1 with HBV-associated Q151M substitution in RT becomes highly susceptible to entecavir: structural insights into HBV-RT inhibition by entecavir (2018) (11)
Long‐term remission in an elderly patient with mantle cell leukemia treated with low‐dose cyclophosphamide (2000) (11)
A Modified P1 Moiety Enhances In Vitro Antiviral Activity against Various Multidrug-Resistant HIV-1 Variants and In Vitro Central Nervous System Penetration Properties of a Novel Nonpeptidic Protease Inhibitor, GRL-10413 (2016) (11)
A Pedigree Harboring a Germ-Line N-Terminal C/EBPα Mutation and Development of Acute Myeloblastic Leukemia with a Somatic C-Terminal C/EBPα Mutation. (2006) (10)
Immunodeficiency Virus In Vitro against Multi-PI-Resistant Human UIC-94017 ( TMC 114 ) with Potent Activity Nonpeptidic Protease Inhibitor ( PI )-Tetrahydrofuranylurethane-Containing bis Novel (2003) (10)
Human T cell leukemia/lymphoma virus I infection and subsequent cloning of normal human B cells. Direct responsiveness of cloned cells to recombinant interleukin 2 by differentiation in the absence of enhanced proliferation (1985) (10)
FUSIDIC ACID, HIV, AND HOST CELL TOXICITY (1988) (10)
Highly Neutralizing COVID-19 Convalescent Plasmas Potently Block SARS-CoV-2 Replication and Pneumonia in Syrian Hamsters (2021) (10)
In Vitro Evaluation of Experimental Agents for Anti‐HIV Activity (1993) (10)
Restoration of immune surface molecules in Kaposi sarcoma-associated herpes virus infected cells by lenalidomide and pomalidomide (2017) (10)
Regulation of the Dimerization and Activity of SARS-CoV-2 Main Protease through Reversible Glutathionylation of Cysteine 300 (2021) (10)
Lipophilic 6-Halo-2′,3′-Dideoxypurine Nucleosides: Potential Antiretroviral Agents Targeting HIV-Associated Neurologic Disorders (1991) (9)
The immunology of HIV infection: implications for therapy. (1992) (9)
AIDS therapies. (1988) (9)
Fractalkine Expression in the Rhesus Monkey Brain During Lentivirus Infection and Its Control by 6-Chloro-2',3'-Dideoxyguanosine (2006) (9)
A new class of dinucleotide analogues. The synthesis of 3′-O-thymidylyl(5′-deoxy-5′-selene-thymidylyl)-Se-phosphoroselenolate, its O-methyl ester and methanephosphonate derivatives. (1994) (9)
Phosphodiester amidates of unsaturated nucleoside analogues: synthesis and anti-HIV activity. (1997) (9)
Inhibition of Human Immunodeficiency Virus Replication by RD6-Y664, a Novel Benzylhydroxylamine Derivative (1999) (9)
Emergence of human immunodeficiency virus type 1 variants containing the Q151M complex in children receiving long-term antiretroviral chemotherapy. (2007) (9)
Immunomodulatory drugs act as inhibitors of DNA methyltransferases and induce PU.1 up-regulation in myeloma cells. (2016) (9)
LESSONS FROM THE PSEUDOROTATIONAL CYCLE : CONFORMATIONALLY RIGID AZT CARBOCYCLIC NUCLEOSIDES AND THEIR INTERACTION WITH REVERSE TRANSCRIPTASE (1998) (9)
The FDA Approved HIV-1 Protease Inhibitors for Treatment of HIV/AIDS (2010) (9)
Ovarian relapse seven years after bone marrow transplantation for B‐cell acute lymphoblastic leukemia: An unusual Krukenberg tumor (2005) (9)
A dose-finding study of glycosylated G-CSF (Lenograstim) combined with CHOP therapy for stem cell mobilization in patients with non-Hodgkin's lymphoma. (2003) (9)
(.+-.)-Dioxolane-T: A New 2′,3′-Dideoxynucleoside Prototype with in vitro Activity Against HIV. (1990) (8)
Acute Promyelocytic Leukemia Harboring STAT5b-RARα Fusion Gene and G596V Mutation in the Stat5b SH2 Domain of the Fusion Gene. (2007) (8)
Discovery of 4-[4-({(3R)-1-butyl-3-[(R)-cyclohexyl(hydroxy)methyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl}methyl)phenoxy]benzoic acid hydrochloride: a highly potent orally available CCR5 selective antagonist. (2011) (8)
Antiviral therapy against HIV infection. (1990) (8)
Design of substituted bis-Tetrahydrofuran (bis-THF)-derived Potent HIV-1 Protease Inhibitors, Protein-ligand X-ray Structure, and Convenient Syntheses of bis-THF and Substituted bis-THF Ligands. (2011) (8)
Design, synthesis, biological evaluation and X-ray structural studies of HIV-1 protease inhibitors containing substituted fused-tetrahydropyranyl tetrahydrofuran as P2-ligands. (2015) (8)
Immunologic issues in anti-retroviral therapy. (1990) (8)
Synthesis and Anti-HIV Activity of 5-Fluorocytallene: N-Dimethylaminomethylene as a Facilitating Group in Acetylene → Allene Isomerization (1994) (8)
Novel Central Nervous System (CNS)-Targeting Protease Inhibitors for Drug-Resistant HIV Infection and HIV-Associated CNS Complications (2019) (8)
Highly-Neutralizing COVID-19-Convalescent-Plasmas Potently Block SARS-CoV-2 Replication and Pneumonia in Syrian Hamsters (2021) (8)
Asymptomatic COVID-19 re-infection in a Japanese male by elevated half-maximal inhibitory concentration (IC50) of neutralizing antibodies (2021) (8)
IMMUNE T CELLS REACTIVE AGAINST HUMAN T-CELL LEUKAEMIA/LYMPHOMA VIRUS (1984) (8)
Diastereoselective Synthesis of 6″-(Z)- and 6″-(E)-Fluoro Analogues of Anti-hepatitis B Virus Agent Entecavir and Its Evaluation of the Activity and Toxicity Profile of the Diastereomers. (2016) (8)
CMCdG, a Novel Nucleoside Analog with Favorable Safety Features, Exerts Potent Activity against Wild-Type and Entecavir-Resistant Hepatitis B Virus (2019) (7)
Halogen Bond Interactions of Novel HIV-1 Protease Inhibitors (PI) (GRL-001-15 and GRL-003-15) with the Flap of Protease Are Critical for Their Potent Activity against Wild-Type HIV-1 and Multi-PI-Resistant Variants (2019) (7)
Therapeutic impact of erythropoietin-encapsulated liposomes targeted to bone marrow on renal anemia. (2014) (7)
Characterization of Human Immunodeficiency Virus Type 1 Strains Resistant to the Non-Nucleoside Reverse Transcriptase Inhibitor RD4–2217 (1999) (7)
Single atom changes in newly synthesized HIV protease inhibitors reveal structural basis for extreme affinity, high genetic barrier, and adaptation to the HIV protease plasticity (2020) (7)
Enhancing Protein Backbone Binding — A Fruitful Concept for Combating Drug-Resistant HIV. (2012) (7)
Successful treatment with low-dose imatinib mesylate of therapy-related myeloid neoplasm harboring TEL-PDGFRB in a patient with acute promyelocytic leukemia (2010) (7)
Successful Treatment of Bing-Neel Syndrome Accompanying Waldenström's Macroglobulinemia with R-MPV: A Case Report. (2015) (7)
Strategies for the combination therapy of HIV infection. (1990) (7)
Micafungin-induced immune hemolysis attacks (2009) (7)
Transcriptional repression of the p15 gene predicts the clinical outcome of acute myeloblastic leukemia with intermediate and adverse cytogenetics (2004) (7)
Spirodiketopiperazine-based CCR5 antagonist: discovery of an antiretroviral drug candidate. (2011) (7)
Synthesis of (Z)-(2,3-bis-Hydroxymethyl)methylenecyclopropane Analogues of Purine Nucleosides (2003) (7)
Active-site deformation in the structure of HIV-1 RT with HBV-associated septuple amino acid substitutions rationalizes the differential susceptibility of HIV-1 and HBV against 4'-modified nucleoside RT inhibitors. (2019) (7)
Anabolism and Mechanism of Action of Ro24‐5098, an Isomer of 2′,3′‐Dideoxyadenosine (ddA) with Anti‐HIV Activity (1990) (7)
Amplification and overexpression of the PRAD1/Cyclin D1 gene in a multiple myeloma cell line. (1998) (6)
Chapter 26. Therapeutic Strategies in the Treatment of AIDS (1988) (6)
Increasing Methylation of the CDKN 2 A Gene Is Associated with the Progression of Adult T-Cell Leukemia 1 (2000) (6)
Thrombopoietin stimulates murine lineage negative, Sca-1+, C-Kit+, CD34- cells: comparative study with stem cell factor or interleukin-3. (2000) (6)
Three cases of aggressive natural killer cell leukemia with a lethal hemorrhagic complication. (2012) (6)
Neutralization activity of sera/IgG preparations from fully BNT162b2 vaccinated individuals against SARS-CoV-2 Alpha, Beta, Gamma, Delta, and Kappa variants (2022) (6)
Antiretroviral chemotherapy against human immunodeficiency virus (hiv) infection: perspective for therapy of hepatitis B virus infection. (1989) (6)
Design, Synthesis, and X-ray Studies of Potent HIV-1 Protease Inhibitors with P2-Carboxamide Functionalities. (2020) (6)
A novel entecavir analogue constructing with a spiro[2.4]heptane core structure in the aglycon moiety: Its synthesis and evaluation for anti-hepatitis B virus activity (2017) (6)
Creation of Low Toxic Reverse-Transcriptase Inhibitory Nucleosides that Prevent the Emergence of Drug-Resistant HIV Variants (2006) (6)
A Plasma Cell Leukemia Patient Showing Bialleic 14q Translocations: t(2;14) and t(11;14) (1999) (6)
Design of HIV Protease Inhibitors Targeting Protein Backbone: An Effective Strategy for Combating Drug Resistance (2008) (6)
Adsorption of Bence–Jones protein to polymethylmethacrylate membrane in primary amyloidosis (2009) (6)
T-cell suppression of immunoglobulin synthesis in ataxia telangiectasia: restriction of suppressor activity to B cells from unrelated donors. (1981) (6)
Design, synthesis, X-ray studies, and biological evaluation of novel macrocyclic HIV-1 protease inhibitors involving the P1'-P2' ligands. (2017) (6)
7-Deaza-7-fluoro modification confers on 4'-cyano-nucleosides potent activity against entecavir/adefovir-resistant HBV variants and favorable safety. (2020) (6)
GRL-079, a Novel HIV-1 Protease Inhibitor, Is Extremely Potent against Multidrug-Resistant HIV-1 Variants and Has a High Genetic Barrier against the Emergence of Resistant Variants (2018) (5)
Induction of necrosis in human myeloma cells by kigamicin. (2008) (5)
Effects of CC chemokine receptor 5 (CCR5) inhibitors on the dynamics of CCR5 and CC-chemokine–CCR5 interactions (2010) (5)
NIH conference. Antiretroviral therapy in AIDS. (1990) (5)
Pharmacokinetics of the Protease Inhibitor KNI-272 in Plasma and Cerebrospinal Fluid in Nonhuman Primates after Intravenous Dosing and in Human Immunodeficiency Virus-Infected Children after Intravenous and Oral Dosing (1998) (5)
A phase I trial of the pharmacokinetics, toxicity, and activity of KNI-272, an inhibitor of HIV-1 protease, in patients with AIDS or symptomatic HIV infection. (1999) (5)
Attempt to Reduce Cytotoxicity by Synthesizing the L-Enantiomer of 4′-C-Ethynyl-2′-Deoxypurine Nucleosides as Antiviral Agents against HIV and HBV (2004) (5)
Synthesis, Anti-HBV, and Anti-HIV Activities of 3'-Halogenated Bis(hydroxymethyl)-cyclopentenyladenines. (2018) (5)
Development of therapeutics for AIDS: structure-based molecular targeting. (2007) (5)
Lipophilic, acid-stable, adenosine deaminase-activated anti-HIV prodrugs for central nervous system delivery. 2. 6-Halo and 6-alkoxy prodrugs of 2'-beta-fluoro-2',3'-dideoxyinosine. (1995) (5)
Implications of the discovery of HTLV-III for the treatment of AIDS. (1985) (5)
Design, Synthesis, Biological Evaluation, and X‐ray Studies of HIV‐1 Protease Inhibitors with Modified P2′ Ligands of Darunavir (2017) (5)
Potent HIV-1 protease inhibitors incorporating squaramide-derived P2 ligands: Design, synthesis, and biological evaluation. (2019) (5)
Development of inhibitors of reverse transcriptase and protease as therapeutics against HIV infection. (1992) (5)
Decreased suppressor T cell activity in patients with hepatic cirrhosis (HC). (1982) (5)
Pancytopenia and Myelodysplastic Changes in Aceruloplasminemia: A Case with a Novel Pathogenic Variant in the Ceruloplasmin Gene (2018) (5)
SARS-CoV-2-Neutralizing Humoral IgA Response Occurs Earlier but Is Modest and Diminishes Faster than IgG Response (2022) (5)
Synthesis of 4′‐Substituted Purine 2′‐Deoxynucleosides and Their Activity against Human Immunodeficiency Virus Type 1 and Hepatitis B Virus (2018) (5)
Synthesis of 4′‐Substituted Purine 2′‐Deoxynucleosides and Their Activity against Human Immunodeficiency Virus Type 1 and Hepatitis B Virus (2018) (5)
EFdA, a reverse transcriptase inhibitor, potently blocks HIV-1 ex vivo infection of Langerhans cells within epithelium. (2014) (5)
Lineage switch with t(6;11)(q27;q23) from T-cell lymphoblastic lymphoma to acute monoblastic leukemia at relapse. (2016) (5)
A Multi-Center, Open-Label, Randomized Controlled Trial to Evaluate the Efficacy of Convalescent Plasma Therapy for Coronavirus Disease 2019: A Trial Protocol (COVIPLA-RCT) (2022) (5)
A case of AIDS-associated oral Kaposi's sarcoma of the tongue (2014) (5)
[Anti-HIV drugs and drug delivery system]. (1998) (4)
Clarithromicin Induces Autophagy in Myeloma Cells. (2006) (4)
Activity and structural analysis of GRL-117C: a novel small molecule CCR5 inhibitor active against R5-tropic HIV-1s (2019) (4)
The use of an HTLV-I-infected human T-cell line (ATH8) in an interleukin-2 bioassay. (1987) (4)
Third-Dose BNT162b2 Vaccination Elicits Markedly High-Level SARS-CoV-2–Neutralizing Antibodies in Vaccinees Who Responded Poorly to a Second Dose in Japan (2022) (4)
Pharmacokinetic Study of Dextran Sulfate in Rats (1990) (4)
[A case of non-secretory myeloma (accompanied with gastric carcinoma) analyzed with plaque forming cell assay]. (1984) (4)
Trial of Antisense RNA Inhibition of HIV Replication and Gene Expression (1991) (4)
[Regression of primary rectal MALT lymphoma after Helicobacter pylori eradication]. (2014) (4)
Chloropyridinyl Esters of Nonsteroidal Anti-Inflammatory Agents and Related Derivatives as Potent SARS-CoV-2 3CL Protease Inhibitors (2021) (4)
Regulation of the Dimerization and Activity of SARS-CoV-2 Main Protease through Reversible Glutathionylation of Cysteine 300 (2021) (4)
An Association Study of HLA with the Kinetics of SARS-CoV-2 Spike Specific IgG Antibody Responses to BNT162b2 mRNA Vaccine (2022) (4)
Spontaneous recovery of hemoglobin and neutrophil levels in Japanese patients on a long-term Combivir containing regimen. (2005) (4)
Structure of HIV-1 protease with KNI-272: a transition state mimetic inhibitor containing allophenylnorstatine. (1995) (4)
Development of Human Immunodeficiency Virus Type 1 Resistance to 4′-Ethynyl-2-Fluoro-2′-Deoxyadenosine Starting with Wild-Type or Nucleoside Reverse Transcriptase Inhibitor-Resistant Strains (2021) (4)
Novel Protease Inhibitors Containing C-5-Modified bis-Tetrahydrofuranylurethane and Aminobenzothiazole as P2 and P2′ Ligands That Exert Potent Antiviral Activity against Highly Multidrug-Resistant HIV-1 with a High Genetic Barrier against the Emergence of Drug Resistance (2019) (4)
Pharmacokinetics studies of 4′‐cyano‐2′‐deoxyguanosine, a potent inhibitor of the hepatitis B virus, in rats (2018) (4)
Amino-acid inserts of HIV-1 capsid (CA) induce CA degradation and abrogate viral infectivity: Insights for the dynamics and mechanisms of HIV-1 CA decomposition (2019) (4)
Design, synthesis, and X-ray studies of potent HIV-1 protease inhibitors incorporating aminothiochromane and aminotetrahydronaphthalene carboxamide derivatives as the P2 ligands. (2018) (3)
Development of HIV-1 protease inhibitors, antiretroviral resistance, and current challenges of HIV/AIDS management (2011) (3)
Synthesis of 4′-C-Ethynyl and 4′-C-Cyano Purine Nucleosides from Natural Nucleosides and Their Anti-HIV Activity (2003) (3)
MUC1/KL-6 expression confers an aggressive phenotype upon myeloma cells. (2018) (3)
Biochemical and Structural Properties of Entecavir-Resistant Hepatitis B Virus Polymerase with L180M/M204V Mutations (2021) (3)
Cover Picture: Probing Multidrug-Resistance and Protein–Ligand Interactions with Oxatricyclic Designed Ligands in HIV-1 Protease Inhibitors (ChemMedChem 11/2010) (2010) (3)
A widely distributed HIV-1 provirus elimination assay to evaluate latency-reversing agents in vitro (2019) (3)
Beyond darunavir: recent development of next generation HIV-1 protease inhibitors to combat drug resistance. (2022) (3)
Restoration of Neutralization Activity Against Omicron BA.2 and BA.5 in Older Adults and Individuals With Risk Factors Following the Fourth Dose of Severe Acute Respiratory Syndrome Coronavirus 2 BNT162b2 Vaccine (2022) (3)
The impact of highly active antiretroviral therapy by the oral route on the CD8 subset in monkeys infected chronically with SHIV 89.6P. (2003) (3)
Potential Anti‐AIDS Drugs. Lipophilic, Adenosine Deaminase‐Activated Prodrugs. (1991) (3)
Synthesis of Acyloxyalkyl Acylphosphonates as Potential Prodrugs of the Antiviral Trisodium Phosphonoformate (Foscarnet Sodium). (1990) (3)
Tryptophanyl phosphoramidates as prodrugs of synadenol and its E-isomer: synthesis and biological activity. (2002) (3)
Escherichia coli Mediated Biosynthesis and in vitro Anti‐HIV Activity of Lipophilic 6‐Halo‐2′,3′‐dideoxypurine Nucleosides. (1991) (3)
Successful use of casirivimab/imdevimab anti-spike monoclonal antibodies to enhance neutralizing antibodies in a woman on anti-CD20 treatment with refractory COVID-19 (2022) (3)
Design, Synthesis, and Evaluation of Anti-HBV Activity of Hybrid Molecules of Entecavir and Adefovir: Exomethylene Acycloguanine Nucleosides and Their Monophosphate Derivatives (2015) (3)
A xenograft model reveals that PU.1 functions as a tumor suppressor for multiple myeloma in vivo. (2017) (3)
JAK 1 mutation analysis in T-cell acute lymphoblastic leukemia cell lines (2009) (3)
A Small Molecule, Shikonin, Dually Functions As a Proteasome Inhibitor and a Necroptosis Inducer In Multiple Myeloma Cells (2013) (3)
Protection of T cells against infectivity and cytopathic effect of HTLV-III in vitro. (1984) (2)
Pharmacokinetic properties of a novel inosine analog, 4′-cyano-2′-deoxyinosine, after oral administration in rats (2018) (2)
Imatinib Mesylate for Refractory Acute Myeloblastic Leukemia Harboring inv(16) and C-KIT Exon 8 Mutation. (2004) (2)
Fluorine Modifications Contribute to Potent Antiviral Activity against Highly Drug-Resistant HIV-1 and Favorable Blood-Brain Barrier Penetration Property of Novel Central Nervous System-Targeting HIV-1 Protease Inhibitors In Vitro (2022) (2)
Effects of islatravir (4'-ethynyl-2-fluoro-2'-deoxyadenosine or EFdA) on renal tubular cells and islatravir's interactions with organic anion transporters. (2021) (2)
Phosphodiester Amidates of Unsaturated Nucleoside Analogues as Anti-HIV Agents (1997) (2)
Hairy cell leukemia responsive to anti-thymocyte globulin used as immunosuppressive therapy for aplastic anemia (2009) (2)
CMCdG, a novel nucleoside analog, exerts potent activity against wild-type and entecavir-resistant HBV with favorable safety feature (2019) (2)
[Reverse transcriptase inhibitors as anti-HIV agents]. (1993) (2)
Lactate Is a Crucial Energy Source For Multiple Myeloma (MM) Cells In Bone Marrow Microenvironment (2013) (2)
Long-term Efficacy of Pegylated Recombinant Human Megakaryocyte Growth and Development Factor in Therapy of Aplastic Anemia (2005) (2)
Mutations in the HIV type 1 integrase of patients receiving long-term dideoxynucleoside therapy do not confer resistance to zidovudine. (2000) (2)
COVID-19 in Japan: An update on national policy, research, clinical practice, and vaccination campaign. (2022) (2)
Advances in Oncology in US and Japan: Focusing on Cancer and Infectious Diseases (2021) (2)
Safety of convalescent plasma therapy for COVID-19 patients and analysis of viral kinetics: a single-center, open-label, single-arm, interventional study in Japan (2022) (2)
[Severe combined immunodeficiency disease and similar combined immunodeficiency disease]. (2001) (2)
A novel HIV-1 protease inhibitor, GRL-044, has potent activity against various HIV-1s with an extremely high genetic barrier to the emergence of HIV-1 drug resistance. (2019) (2)
Development and validation of a cell-based assay system to assess human immunodeficiency virus type 1 integrase multimerization. (2016) (2)
Potent and biostable inhibitors of the main protease of SARS-CoV-2 (2022) (2)
A Therapeutic Strategy to Combat HIV-1 Latently Infected Cells With a Combination of Latency-Reversing Agents Containing DAG-Lactone PKC Activators (2021) (2)
Droplet digital PCR assay provides intrahepatic HBV cccDNA quantification tool for clinical application (2022) (2)
Aerobic Glycolysis: A Possible Target for Treating Multiple Myeloma (MM) with High Serum LDH Levels (2011) (2)
17 – Toward the Rational Design of Antiretroviral Therapy for Human Immunodeficiency Virus (HIV) Infection (1991) (2)
Design and synthesis of novel HIV-1 protease inhibitors incorporating oxyindoles as the P2'-ligands. (2006) (2)
Potential Anti-AIDS Drugs. 2′,3′-Dideoxycytidine Analogues. (1987) (2)
[Allergic reaction against an emulsifier, HCO-60, contained in multamin and enocitabine]. (2003) (1)
Successful Treatment of Amyloid Light-chain Amyloidosis in a Charcot-Marie-Tooth Disease Patient with Lenalidomide, Cyclophosphamide, and Dexamethasone. (2016) (1)
New insights into immunological function of Langerhans cells in HIV in vitro and ex vivo infection (2016) (1)
Early phase dynamics of traceable mCherry fluorescent protein‐carrying HIV‐1 infection in human peripheral blood mononuclear cells‐transplanted NOD/SCID/Jak3‐/‐ mice (2017) (1)
PU.1-Induced IRF4 Down-Regulation and Subsequent IRF7 up-Regulation in Myeloma Cells (2015) (1)
Neutralization activity of IgG antibody in COVID‑19‑convalescent plasma against SARS-CoV-2 variants (2023) (1)
Human T-cell leukemia/lymphoma viruses (HTLV): a unique family of pathogenic retroviruses. (1985) (1)
[Aspergillosis of masticator space including mandibular bone responding to itraconazole treatment in a diabetic adult: case report]. (2008) (1)
Effect of streptococcal preparation, OK-432 on cultured spontaneous cell mediated cytotoxicity (CSCMC) and Ig production in vitro (1981) (1)
Immunosenescence and defense mechanisms (1980) (1)
Antiretroviral chemotherapy against AIDS (1995) (1)
Conserved hydrogen-bonding network of P2 bis-tetrahydrofuran (2014) (1)
Treatment of therapy-related acute myeloid leukemia occurring in elderly non-Hodgkin lymphoma patients with low-dose cytarabine, aclarubicin and granulocyte colony-stimulating factor. (2009) (1)
Absence of Kaposi’s sarcoma-associated herpesvirus (KSHV) in bone marrow cells from Japanese myeloma patients (1999) (1)
Determination of 2'-beta-fluoro-2',3'-dideoxyadenosine, an experimental anti-AIDS drug, in human plasma by high-performance liquid chromatography. (1998) (1)
Decrease in Sensitivity of PIG-A-Mutant Cells to Natural Killer Cells Conferred by Missing of Stress-Inducible Membrane Proteins ULBPs. (2004) (1)
Complete remission achieved in a multiple myeloma patient with elevated serum KL-6 level by a combination regimen with bortezomib, cyclophosphamide, and dexamethasone. (2014) (1)
Synthesis and evaluation of the anti-hepatitis B virus activity of 4′-Azido-thymidine analogs and 4′-Azido-2′-deoxy-5-methylcytidine analogs: structural insights for the development of a novel anti-HBV agent (2020) (1)
Hepatogenic Potential of Stem Cells and Lymphoid Precursors. (2005) (1)
Neutralizing antibodies after three doses of the BNT162b2 vaccine, breakthrough infection, and symptoms during the Omicron-predominant wave (2022) (1)
Modulation of the antiretroviral activity and anabolism of purine-2′,3′dideoxynucleoside analogs by inhibitors of IMP dehydrogenase (1991) (1)
Focusing on global health and medicine. (2019) (1)
Oral Melphalan, Dexamethasone, and Thalidomide for the Treatment of Refractory Multiple Myeloma (2007) (1)
Frequent detection of hprt gene mutations in paroxysmal nocturnal hemoglobinuria (2000) (1)
A case of human immunodeficiency virus-related heart failure resembling dilated cardiomyopathy but accompanied by high cardiac output. (2014) (1)
Identification of SARS-CoV-2 Mpro inhibitors containing P1’ 4-fluorobenzothiazole moiety highly active against SARS-CoV-2 (2023) (1)
Lessons from the Pseudorotational Cycle: Conformationally Rigid AZT Carbocyclic Nucleosides and Their Interaction with Reverse Transcriptase. (1999) (1)
Erratum: (R)-(-)- and (S)-(+)-adenallene: Synthesis, absolute configuration, enantioselectivity of antiretroviral effect, and enzymic deamination (Journal of Medicinal Chemistry (1992) 35 (4098-4102)) (1993) (1)
Hypersusceptibility mechanism of Tenofovir-resistant HIV to EFdA (2013) (1)
SARS-CoV-2 breakthrough infection during the Delta-dominant epidemic and neutralizing antibodies against Omicron in comparison with the third dose of BNT162b2: a matched analysis (2022) (1)
Development of the First AIDS Drugs: AZT and Other Dideoxynueosides (2013) (1)
Toward targeted therapy for HIV infection (1990) (1)
Mutations in the Receptor Tyrosine Kinase Pathway Are Associated with Clinical Outcome in Patients with Acute Myeloblastic Leukemia Harboring t(8;21)(q22;q22). (2004) (1)
Generation of Angiotensin-Converting Enzyme 2/Transmembrane Protease Serine 2-Double-Positive Human Induced Pluripotent Stem Cell-Derived Spheroids for Anti-Severe Acute Respiratory Syndrome Coronavirus 2 Drug Evaluation (2022) (1)
Design, Synthesis, Protein-ligand X-ray Structures and Biological Evaluation of a Series of Novel Macrocyclic HIV-1 Protease Inhibitors to Combat Drug-resistance (2010) (1)
Chemistry and Anti‐HIV Properties of 2′‐Fluoro‐2′,3′‐ dideoxyarabinofuranosylpyrimidines. (1992) (1)
Consistency of the results of rapid serological tests for SARS-CoV-2 among healthcare workers in a large national hospital in Tokyo, Japan. (2021) (1)
Pharmacokinetic Properties of Orally Administered 4'-Cyano-2'-deoxyguanosine, a Novel Nucleoside Analog Inhibitor of the Hepatitis B Virus, in Viral Liver Injury Model Rats. (2020) (1)
Inhibition Mechanism of EFdA, a Highly Potent Inhibitor of HIV Reverse Transcriptase [abstract] (2010) (0)
X-ray crystal structure of wild type HIV-1 protease in complex with GRL-121 (2017) (0)
An improved droplet digital PCR assay reveals the stability of intrahepatic hepatitis B virus cccDNA. (2021) (0)
Downregulation of PU.1 Is Required for Subtype of Multiple Myeloma. (2005) (0)
Leu 3+ autoreactive T cell clones have both helper and suppressor function (1985) (0)
Erratum to “Tryptophanyl phosphoramidates as prodrugs of synadenol and its E-isomer: synthesis and biological activity” [Bioorg. Med. Chem. Lett. 12 (2002) 2467] ☆ (2002) (0)
PenetrationMay Allow Blood-Brain Barrier and Possess Favorable Lipophilicity Vitro In Replication of Multi-PI-Resistant HIV-1 Protease Inhibitors (PIs) That Inhibit the Difluoride-Containing Nonpeptidic HIV-1 GRL-04810 and GRL-05010, (2014) (0)
Synthesis and Anti‐HIV Activity of Isonucleosides. (1992) (0)
Design and Synthesis of 4'-Cyano Dideoxy Isonucleosides and Their Activity against HIV-1 and HBV (2020) (0)
PU.1 Is Downregulated in a Subset of Multiple Myeloma by the Methylation of Its -17 kb Upstream Regulatory Region and the Promoter. (2006) (0)
The WIPE assay for selection and elimination of HIV-1 provirus in vitro using latency-reversing agents (2019) (0)
INCREASED MEMORY T-CELLS AND DECREASED NAIVE T-CELLS IN HUMAN T-CELL LEUKEMIA VIRUS INFECTED INDIVIDUALS (1999) (0)
[Simultaneous occurrence of acute myelogenous leukemia and multiple myeloma (IgG1-lambda) without previous chemotherapy--report of a case]. (1982) (0)
Medicament for the treatment of HIV-infected mammal (1999) (0)
[Molecular mechanisms for the emergence of drug-resistant HIV-1]. (2000) (0)
X-ray crystal structure of wild type HIV-1 protease in complex with GRL-004 (2020) (0)
The present state of studies on AIDS. (1988) (0)
A novel gene expression profiling system using quantitative PCR. For clinical research and drug development. (2002) (0)
A familial cluster of severe coronavirus disease 2019 that required intubation of all family members (2020) (0)
Specific and non specific binding inhibition of radiolabeled human immunodeficiency virus (1988) (0)
Treatment of acquired immunodeficiency syndrome. (1990) (0)
articleCharacterization of monocyte / macrophage subsets in the skin and peripheral blood derived from patients with systemic sclerosis (2015) (0)
Extramedullary tumors presenting double vision in patients with t(8;21)(q22;q22) acute myeloid leukemia lacking mutations in the receptor tyrosine kinase genes KIT or FLT3. (2010) (0)
Micafungin-induced immune hemolysis attacks (International Journal of Hematology (2009) 89(139-141) (DOI 10.1007/s12185-008-0246-5)) (2009) (0)
Crystal structure of wild type HIV-1 protease in complex with GRL-10413 (2016) (0)
2', 3'-Dideoxynucleoside Analogues : Development of Anti-Viral Therapy for HTLV-III/LAV Associated Diseases (1986) (0)
Evaluation of Darunavir-derived HIV-1 protease inhibitors incorporating P2' amide-derivatives: Synthesis, biological evaluation and structural studies. (2023) (0)
Immunogenicity and safety of single booster dose of KD-414 inactivated COVID-19 vaccine in adults: An open-label, single-center, non-randomized, controlled study in Japan. (2023) (0)
Design, Synthesis and Evaluation of Anti-Hepatitis B Virus (Hbv) Activity of Novel Entecavir Analogues Having 4′-Cyano-6″-Fluoromethylenecyclopentene Skeletons as an Aglycone Moiety (2023) (0)
Effects of a novel hepatitis B antiviral drug in renal organic acid transporters (2022) (0)
A Novel Anti-HBV Agent, E-CFCP, restores Hepatitis B virus (HBV)-induced Senescence-associated Cellular Markers Perturbation in Human Hepatocytes. (2023) (0)
Cell-Derived Factor (SDF)-1: Cell Survival Promotion and Priming Effects of SDF-1 on CD4 T Cells (2001) (0)
Strategy for Development of Therapeutics for HIV/AIDS, Chronic Hepatitis B, and SARS-CoV-2/COVID-19 (2022) (0)
Structural features in common of HBV and HIV-1 resistance against chirally-distinct nucleoside analogues entecavir and lamivudine (2020) (0)
Pre-infection neutralizing antibodies, Omicron BA.5 breakthrough infection, and long COVID: a propensity score-matched analysis (2023) (0)
Synthesis and evaluation of DAG-lactone derivatives with HIV-1 latency reversing activity (2023) (0)
Regulation of Retroviral and SARS-CoV-2 Protease Dimerization and Activity through Reversible Oxidation (2022) (0)
Activity and structural analysis of GRL-117C: a novel small molecule CCR5 inhibitor active against R5-tropic HIV-1s (2019) (0)
SARS-CoV-2-neutralizing humoral IgA response occurs earlier but modest and diminishes faster compared to IgG response (2022) (0)
Omicron BA.1 neutralizing antibody response following Delta breakthrough infection compared with booster vaccination of BNT162b2 (2023) (0)
PU.1-Induced Growth Arrest and Apoptosis in Classical Hodgkin Lymphoma Cells (2011) (0)
Antibody responses after two doses of SARS-CoV-2 mRNA-1273 vaccine in an individual with history of COVID-19 re-infection (2022) (0)
Long-term inhibition of human T-ly: lymphadenopathy-associated virus ( virus) DNA synthesis and RNA exp protected by 2',3'-dideoxynucleosid (2016) (0)
Crystal Structure of SARS-CoV-2 main protease in complex with an inhibitor GRL-2420 (2020) (0)
Exploration of imatinib and nilotinib-derived templates as the P2-Ligand for HIV-1 protease inhibitors: Design, synthesis, protein X-ray structural studies, and biological evaluation (2023) (0)
Neutralising activity and antibody titre in 10 patients with breakthrough infections of the SARS-CoV-2 Omicron variant in Japan (2022) (0)
Preserved SARS-CoV-2 neutralizing IgG activity of in-house manufactured COVID-19 convalescent plasma (2022) (0)
Comparative enzymatic study of HIV reverse transcriptase resistant to multiple 2,3-dideoxynucleoside 5-triphosphates (1996) (0)
Phenotypic and Genotypic Comparisons of Human T-Cell Leukemia Virus Type 1 Reverse Transcriptases from Infected T-Cell Lines and Patient Samples (cid:1) (2007) (0)
HIV-1 with HBV-associated Q151M substitution in RT becomes highly susceptible to entecavir: structural insights into HBV-RT inhibition by entecavir (2018) (0)
Effects of a novel hepatitis B anti-viral drug E-CFCP in renal organic acid transporters. (2022) (0)
Comparison of neutralization activity against Omicron BA.2/BA.5 in sera from HCWs receiving heterologous/homologous COVID-19 vaccines (2023) (0)
Allogeneic bone marrow transplantation after L-asparaginase-induced pancreatitis in a patient with acute lymphoblastic leukemia. (2008) (0)
A case of COVID-19 reinfection in a hemodialysis patient: the role of antibody in SARS-CoV-2 infection (2022) (0)
Cyclobut-A (I) and Cyclobut-G (II): Broad-Spectrum Antiviral Agents with Potential Utility for the Therapy of AIDS. (1990) (0)
Possible new disease entity of AL amyloidosis induced by deposition of IGLC2 (2015) (0)
Both 5′ and 3′ Distal Regulatory Elements Are Required for Human CD34 Gene Expression. (2004) (0)
Proliferative responsiveness of B cells in primary immunodeficiency (1983) (0)
Derivatives of 2-haloadenosina 4'-C-substituted. (2005) (0)
Growth Elements and the Promoter Is Required for Myeloma Cell Down-regulation of PU . 1 by Methylation of Distal Regulatory (2007) (0)
Characteristics of Chronic-Phase CML Patients Having Durable Cytogenetic Response to Low-Dose Imatinib (2008) (0)
LEUKEMOGENESIS AND PROGRESSION OF ADULT T-CELL LEUKEMIA (1999) (0)
Fitness test and methods for reducing HIV resistance to therapy (1999) (0)
Agents for the treatment of AIDS caused by viruses of infectious dementia (1989) (0)
X-ray crystal structure of wild type HIV-1 protease in complex with GRL-001 (2019) (0)
Mathematical Epidemiological Model of the Propagation and Prevention of Infectious Diseases Considering COVID-19 Vaccination (2021) (0)
[Progress in AIDS therapy]. (2006) (0)
IMMUNOSELECTION OF PIG-A MUTANT CELLS MISSING ULBP (2005) (0)
1-(3-Cyano-2,3-dideoxy-β-D-erythro-pentofuranosyl)thymine (Cyanothymidine) (I): Synthesis and Antiviral Evaluation Against Human Immunodeficiency Virus. (1989) (0)
Immunological function of Langerhans cells in HIV in vitro and ex vivo infection (2016) (0)
Summary of Research Activities by Disease Categories Infectious Diseases and Biodefense By (0)
[Multi-drug resistant pathogens, positioning of various drugs, and their appropriate use: 1. Anti-HIV agents]. (2003) (0)
Clinically Used Antiretroviral Drugs -Deoxyadenosine with ' -Ethynyl-2-Fluoro-2 ' Evaluation of Combinations of 4 (2014) (0)
Kigamicin Induces Necrosis to Human Myeloma Cells by Disruption of Cell Cycle Regulation. (2006) (0)
Crystal structure of multidrug-resistant clinical isolate A02 HIV-1 protease in complex with non-peptidic inhibitor, GRL0519 (2016) (0)
Structures of HIV-1 reverse transcriptase with HBV-associated triple mutations in complex with chirally-distinct nucleoside analogues, ETV-TP and 3TC-TP (2020) (0)
Conditionally Expressed PU.1 Transactivates TRAIL Gene and Induces Apoptosis in Myeloma Cell Lines. (2008) (0)
Proficiency testing and methods for reducing HIV resistance to therapy (1999) (0)
Anti-retroviral compound (1988) (0)
Functions of Human T Lymphocytes Age-Related Changes in the Subsets and (2012) (0)
Design and activity of protease active site-targeted anti-HIV agents containing allophenylnorstatine (1993) (0)
Kynostatins, highly selective and superpotent HIV protease inhibitors: Conformationally constrained tripeptides containing allophenylnorstatine as a transition-state mimic (1995) (0)
-6-fluoro-9-(2,3-dideoxy-b-d-glycero-pentofuranosyl)-9h-purines and their use asantiviral agents (1991) (0)
Nucleosides 4'-ethynyl-c. (2000) (0)
Drugs for treatment of HIV-infected mammals (1999) (0)
X-ray crystal structure of darunavir-resistant HIV-1 protease (P51) in complex with GRL-003 (2020) (0)
Decreased CD138 Expression in Myeloma Cells: A Potential Indicator of Poor Prognosis and Aberrant Differentiation, (2011) (0)
Familial Acute Myeloblastic Leukemia with a Dominant Negative Mutation in the CEBPA Gene. (2005) (0)
X-ray crystal structure of wild type HIV-1 protease in complex with GRL-0476 (2016) (0)
X-ray crystal structure of darunavir-resistant HIV-1 protease (P30) in apo state (2020) (0)
A JAK2-V617F Activating Mutation in Addition to C-KIT and FLT3 Mutations Is Associated with Clinical Outcome in Patients with t(8;21)(q22;q22;) Acute Myeloid Leukemia. (2007) (0)
Ic issues in anti-retrovirai lherapy (1990) (0)
Activity against Human Immunodeﬁciency Virus Type 1, Intracellular Metabolism, and Effects on Human DNA Polymerases of 4 (cid:2) -Ethynyl-2-Fluoro-2 (cid:2) -Deoxyadenosine (cid:1) (2007) (0)
Potent Activity of a Nucleoside Reverse Transcriptase Inhibitor, 4 (cid:2) -Ethynyl-2-Fluoro-2 (cid:2) -Deoxyadenosine, against Human Immunodeﬁciency Virus Type 1 Infection in a Model Using Human Peripheral Blood Mononuclear Cell-Transplanted NOD/SCID Janus Kinase 3 Knockout Mice (cid:1) (2009) (0)
Differential Antiviral Activity Of A Phosphorothioate Anti-rev Antisense Oligodeoxynucleotide Against Hiv-1 (1993) (0)
Increase of the Adenallene anti‐HIV Activity in Cell Culture Using Its Bis(tBuSATE) Phosphotriester Derivatives. (2002) (0)
X-ray crystal structure of wild type HIV-1 protease in complex with GRL-085 (2016) (0)
HIV virions produced by cells treated with the HIV-1 protaase Inhibitor KNI-272 do not acquire Inactivity after viral budding (1996) (0)
Aberrantly Hypermethylated Genes in Adult T-Cell Leukemia Cells: The Implications in the Leukemogenesis. (2004) (0)
Generation of Antigen-specific Helper-inducer Clones . (2003) (0)
Molecular and cellular analyses of HLA class II-associated susceptibility to autoimmune diseases in the Japanese population (2001) (0)
Crystal structure of multidrug-resistant clinical isolate A02 HIV-1 protease in complex with amprenavir (2014) (0)
[Recent challenges and progress in AIDS therapy--emergence of drug resistant HIV-1 variants]. (1999) (0)
Pharmacokinetics of 4'-cyano-2'-deoxyguanosine, a novel nucleoside analog inhibitor of the resistant hepatitis B virus, in a rat model of chronic kidney disease. (2020) (0)
Immunologic analysis of peripheral blood lymphocytes from patients with primary immunodeficiency (1982) (0)
X-ray crystal structure of darunavir-resistant HIV-1 protease (P30) in complex with GRL-001 (2020) (0)
Clinical Features of Human T-Cell Leukemia/Lymphoma Virus (HTLV) Associated T-Cell Neoplasms (1984) (0)
A New Class of Dinucleotide Analogues. The Synthesis of 3′‐O‐ Thymidylyl(5′‐deoxy‐5′‐selene‐thymidylyl)‐Se‐phosphoroselenolate, Its O‐Methyl Ester and Methanephosphonate Derivatives. (1994) (0)
Treatment of MGUS by Hesperetin, potentially Delaying/Blocking the Conversion of MGUS to Symptomatic Myeloma. (2009) (0)
P2-21-3TWO CASES OF PRIMARY B CELL LYMPHOMA OF CAUDA EQUINA (2014) (0)
Dendritic Cells Enriched Populations of HIV-Infected Proliferation and IL-2 Production by Highly T Cell + Decreased Stimulation of CD4 (2003) (0)
[Recent and future development of anti-HIV agents]. (2010) (0)
Crystal structure of wild type HIV-1 protease in complex with non-peptidic inhibitor, GRL007 (2013) (0)
Complete remission achieved by a combination regimen with bortezomib, cyclophosphamide, and dexamethasone in a multiple myeloma patient with elevated serum KL-6 level (2014) (0)
Monocarboxylate Transporters Play an Important Role in Aerobicglycolysis in Multiple Myeloma (2012) (0)
Appearance of Stress-Inducible Membrane Proteins ULBP on Blood Cells of Patients with PNH, Aplastic Anemia, and MDS: Possible Implication of ULBP in Immune-Mediated Marrow Injury. (2005) (0)
Conditional Knockout of Sfpi1 in Post GC B and Plasma Cells Induces B Cell Lymphoma and Plasma Cell Neoplasm (2014) (0)
MOLECULAR TARGETING APPROACH AND XENOBIOTIC CONSIDERATIONS FOR DEVELOPMENT OF AIDS THERAPEUTICS (2008) (0)
Isolation of Mesenchymal Stem Cells from Human Bone Marrow Using Aldehyde Dehydrogenase as a Marker. (2007) (0)
Synthesis and Anti‐HIV Activity of 5‐Fluorocytallene: N‐ Dimethylaminomethylene as a Facilitating Group in Acetylene → Allene Isomerization. (1995) (0)
X-ray crystal structure of darunavir-resistant HIV-1 protease (P30) in complex with GRL-003 (2020) (0)
X-ray crystal structure of wild type HIV-1 protease in complex with GRL-08513 (2020) (0)
Antibody titers and neutralizing activity in cases of COVID-19 after a single dose of vaccination (2022) (0)
Medication for treating mammals infected with HIV. (1999) (0)
X-ray crystal structure of wild type HIV-1 protease in complex with GRL-097 (2016) (0)
In Vitro Multi-PI-Resistant HIV-1 Variants Replication of a Wide Spectrum of Protease Inhibitor (PI), Potently Suppresses Ligand-Containing Nonpeptidic HIV-1 GRL-0519, a Novel Oxatricyclic (2014) (0)
X-ray crystal structure of wild type HIV-1 protease in complex with GRL-015 (2016) (0)
Synthesis of (Z)-(2,3-Bis-hydroxymethyl)methylenecyclopropane Analogues of Purine Nucleosides. (2003) (0)
The promising anti-HIV agent kynostatin (KNI)-272: A highly selective and super-active HIV protease inhibitor containing allophenylnorstatine (1994) (0)
X-ray crystal structure of wild type HIV-1 protease in complex with GRL-09510 (2017) (0)
Front Cover: Design of Highly Potent, Dual‐Acting and Central‐Nervous‐System‐Penetrating HIV‐1 Protease Inhibitors with Excellent Potency against Multidrug‐Resistant HIV‐1 Variants (ChemMedChem 8/2018) (2018) (0)
X-ray crystal structure of wild type HIV-1 protease in complex with GRL-087-13 (2019) (0)
[AIDS therapy with reverse transcriptase inhibitors]. (1993) (0)
GRL-09510, a Unique P2-Crown-Tetrahydrofuranylurethane -Containing HIV-1 Protease Inhibitor, Maintains Its Favorable Antiviral Activity against Highly-Drug-Resistant HIV-1 Variants in vitro (2017) (0)
Crystal structure of wild type HIV-1 protease in complex with non-peptidic inhibitor, GRL008 (2013) (0)
Novel Inhibition Mechanism and Potent Activity of Translocation-deficient Reverse Transcriptase Inhibitors (2008) (0)
Guideline for Antiretroviral Therapy of HIV Infection: Summary and Perspective (1999) (0)
Development of Resistance to 4’-Ethynyl-2-Fluoro-2’-Deoxyadenosine (EFdA) by WT and Nucleoside Reverse Transcriptase Inhibitor Resistant Human Immunodeficiency Virus Type 1 (2020) (0)
Design, Synthesis and X‐Ray Structural Studies of Potent HIV‐1 Protease Inhibitors Containing C‐4 Substituted Tricyclic Hexahydro‐Furofuran Derivatives as P2 Ligands (2022) (0)
HIV-1 Integrase Inhibitors Primary Mechanism of Action of Allosteric Aberrant Protein Multimerization as the The A 128 T Resistance Mutation Reveals Molecular Bases of Disease : (2013) (0)
4′-Ethynyl nucleoside analogues: Potent inhibitors active against multi-drug-resistant HIV variants (2001) (0)
Upregulation of TRAIL in Myeloma Cells Correlates with Skeletal-Related Events. (2009) (0)
CD125-Expressing Myeloma: A Subgroup of Multiple Myeloma (MM) with Immature Phenotype, Endoplasmic Reticulum Stress Response and Low Sensitivity to Bortezomib (2010) (0)
SUCCESSFUL ALLOGENEIC PERIPHERAL BLOOD STEM CELL TRANSPLANTATION IN A PATIENT WITH ADULT T-CELL LEUKEMIA (1999) (0)
X-ray crystal structure of darunavir-resistant HIV-1 protease (P51) in complex with GRL-001 (2020) (0)
482 GRL-142, a novel HIV-1 protease inhibitor, potently blocks HIV-1 ex vivo infection of Langerhans cells within epithelium (2019) (0)
Development of Therapeutics for HIV/AIDS, CHB and COVID-19 (2022) (0)
UIC-94017/TMC114: A Novel Nonpeptidic Protease Inhibitor Containing bis-Tetrahydrofuranyl Urethane (bis-THF) Potent against Multi-PI-Resistant HIV In Vitro (2005) (0)
X-ray crystal structure of wild type HIV-1 protease in complex with GRL-063 (2020) (0)
Novel nucleoside reverse transcriptase inhibitor (4’-Ethynyl-2-Fluoro-2’-Deoxyadenosine) completely blocks HIV Infection of Langerhans Cells (2013) (0)
Chemistry and Anti-HIV Activity of 2′-β-Fluoro-2′,3′- dideoxyguanosine. (1995) (0)
HIV-1 and HTLV-1:From Bench to Bedside (2006) (0)
Novel protease inhibitors markedly adapting to the structural plasticity of HIV-1 protease exert extreme potency with high genetic barrier (2018) (0)
Raltegravir blocks the infectivity of red‐fluorescent‐protein (mCherry)‐labeled HIV‐1JR‐FL in the setting of post‐exposure prophylaxis in NOD/SCID/Jak3−/− mice transplanted with human PBMCs (2018) (0)
Chemotherapy for AIDS. (1994) (0)
Amino-acid inserts of HIV-1 capsid (CA) induce CA degradation and abrogate viral infectivity: Insights for the dynamics and mechanisms of HIV-1 CA decomposition (2019) (0)
[Structure-guided molecular-targeting approach for development of AIDS therapeutics]. (2010) (0)
Induction of Autophagy to Myeloma Cells by Thalidomide and Clarithromycin. (2005) (0)
[Understanding of AIDS and its control]. (2002) (0)
Bufalin induces apoptosis in myeloma cells through DNA damage at hypoxic conditions (2015) (0)
Hypoxia Reduces CD138 Expression and Induces Immature Phenotype in Myeloma Cells (2012) (0)
Diesters Phosphoro-l-Alaninate Analogues and Their -Methylenecyclopropane Nucleoside E - and Z Virus Activities of In Vitro Anti-Human Immunodeficiency (2014) (0)
IDH2 Mutations Have An Unfavorable Impact in Elderly Patients with Acute Myeloid Leukemia (2011) (0)
Design of HIV protease inhibitors with effective antiviral activity: Use of allophenylnorstatine as a transition-state mimic (1993) (0)
Microarray Analysis of PU.1-Induced Growth Arrest and Apoptosis of Myeloma Cell Lines. (2007) (0)
X-ray crystal structure of darunavir-resistant HIV-1 protease (P30) in complex with GRL-142 (2020) (0)
Aspergillosis of the skin associated with malignant lymphoma (1977) (0)
Accumulation Of Gene Alterations Of TP53, Crebbp and IKZF1 Is a Prognostic Factor In Adult Acute Lymphoblastic Leukemia (2013) (0)
P-39 2'-DEXY-4'-C-ETHYNYL-2-FLUOROADENOSINE, A NRTI THAT COULD BE AN IDEAL DRUG FOR BOTH HIV-AND HBV-INFECTIONS (2006) (0)
Recent Progress in HIV Drug Resistance Research-From Bench to Bedside- (2005) (0)
X-ray crystal structure of wild type HIV-1 protease in complex with GRL-002 (2020) (0)
[Inhibitors of HIV-1 reverse transcriptase and protease as chemotherapeutics for AIDS]. (1991) (0)
X-ray crystal structure of wild type HIV-1 protease in complex with GRL-003 (2019) (0)
Survival Promotion and Priming Effects ( SDF )-1 : Cells to Stromal Cell-Derived Factor T + Diverse Transcriptional Response of CD 4 (2001) (0)
[Case of Sézary syndrome with accentuated hyperimmunoglobulinemia E--evidence for malignant proliferation of IgE-specific helper T lymphocytes]. (1983) (0)
Structures of HIV-1 reverse transcriptase with HBV-associated septuple mutations in complex with DNA and ETV-TP (2019) (0)
3'-Azido-3'-deoxythymidine (BWA509U): Anantiviral agentthat inhibits theinfectivity andcytopathic effect ofhuman T-lymphotropic virus typeIII/lymphadenopathy-associated virus invitro (inhibition ofhumanT-lymphotropic virus typemI/thymidmne analogue/acquired immunedeficiency syndrome/retrovirus) (1985) (0)
Activation of human immunodeficiency virus 1 hiv 1 by dna demethylation (1991) (0)
Crystal structure of wild type HIV-1 protease in complex with darunavir (2013) (0)
Xenograft Models of Multiple Myeloma Reveal That PU.1 Serves As a Tumor Suppressor for Multiple Myeloma (2014) (0)
X-ray crystal structure of wild type HIV-1 protease in complex with GRL-08613 (2020) (0)
Transdifferentiation of Bone Marrow-Derived Cells Co-Cultured with Fetal Liver Cells into Hepatic-Like Cells without Fusion. (2004) (0)
HIV-1 reverse transcriptase complexed with DNA and ETV-TP , an anti-HBV drug (2018) (0)
Zidovudine resistance of human immunodeficiency virus. Discussion (1990) (0)
Wow, Scientists Are So Cool! (2009) (0)
Single atom changes in newly synthesized HIV protease inhibitors reveal structural basis for extreme affinity, high genetic barrier, and adaptation to the HIV protease plasticity (2020) (0)
X-ray crystal structure of darunavir-resistant-P51 HIV-1 protease in complex with GRL-121 (2019) (0)
[Chemotherapy of AIDS--recent progress]. (1997) (0)
X-ray crystal structure of wild type HIV-1 protease in complex with GRL-084-13 (2019) (0)
[The current status of structured treatment interruption]. (2002) (0)
Nucleosides OD process for its preparation (1988) (0)
killer cells in vitro Decreased susceptibility of leukemic cells with PIG-Amutation to natural (2013) (0)
[Management of bone lesions in multiple myeloma]. (2006) (0)
Symposium 7 “Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Individuals in Japan” (2007) (0)
X-ray crystal structure of darunavir-resistant-P51 HIV-1 protease in complex with GRL-142 (2019) (0)
[Antiviral chemotherapy for AIDS: dideoxynucleosides and clinical application]. (1990) (0)
Subject Index Vol. 101, 1999 (1999) (0)
Inhibition of renal tubular cells by novel anti-HIV therapeutic agents and interaction with organic anion transporters (2020) (0)
Erratum to: Micafungin-induced immune hemolysis attacks (2009) (0)
[CD4-derivatives therapy of HIV carriers]. (1993) (0)
Prognostic Impact and Concurrent Genetic Alterations of CEBPA Double Mutations in Adults with Cytogenetically Intermediate-Risk Acute Myeloid Leukemia. (2012) (0)
X-ray crystal structure of wild type HIV-1 protease in complex with GRL-142 (2017) (0)
[Case of common variable hypogammaglobulinemia associated with gastric carcinoma]. (1983) (0)
[HIV-1 infection and its treatment]. (2003) (0)
Contents Vol. 101, 1999 (1999) (0)
Identification of Hepatic Progenitors Having No Hematopoietic Potential in Murine Bone Marrow. (2006) (0)
Deposition of Lambda Chain Constant Region within AL-Amyloid Lesion (2014) (0)
Production of TRAIL by Multiple Myeloma Cells: a Potential Prediction Marker for Skeletal-Related Events (2010) (0)

This paper list is powered by the following services:

Other Resources About Hiroaki Mitsuya

en.wikipedia.org

What Schools Are Affiliated With Hiroaki Mitsuya?

Hiroaki Mitsuya is affiliated with the following schools: